



2019 Medicare Part D Prior Authorization Requirements

Effective: February 1, 2019

ACTEMRA

Drugs

ACTEMRA, ACTEMRA ACTPEN

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

MAY NOT USE ACTEMRA CONCURRENTLY WITH OTHER BIOLOGIC THERAPIES.

Required Medical Information

INITIAL CRITERIA: (1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) MEDICAL CHART DOCUMENTATION OF BASELINE DISEASE ACTIVITY AND/OR FUNCTIONAL ASSESSMENT AND TREATMENT GOALS, AND (3) FOR RHEUMATOID ARTHRITIS AND JUVENILE IDIOPATHIC ARTHRITIS ONLY, DOCUMENTATION OF MEDICAL CONTRAINDICATIONS OR INADEQUATE RESPONSE WITH ENBREL AND HUMIRA. RENEWAL CRITERIA: MEDICAL CHART DOCUMENTATION THAT TREATMENT GOALS HAVE BEEN MET FOR THERAPY.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY RHEUMATOLOGY

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

ACTIMMUNE

Drugs

ACTIMMUNE

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

FOR NEW START PATIENTS: DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D.

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

LIMITED TO A MAXIMUM DOSE OF 50 MCG PER SQUARE METER 3 TIMES WEEKLY.

AIMOVIG

Drugs

AIMOVIG AUTOINJECTOR, AIMOVIG AUTOINJECTOR (2 PACK), AJOVY, EMGALITY PEN, EMGALITY SYRINGE

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

INITIAL CRITERIA: (1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) PATIENT HAS GREATER THAN OR EQUAL TO 4 MIGRAINE DAYS PER MONTH, AND (3) PATIENT HAS A DOCUMENTED INADQUATE RESPONSE OR MEDICAL CONTRAINDICATION TO AT LEAST TWO STANDARD PROPHYLACTIC PHARMACOLOGIC THERAPIES, AT LEAST ONE DRUG EACH FROM A DIFFERENT PHARMACOLOGIC CLASS SUCH AS ANTICONVULSANT, BETA-BLOCKER, ANTIDEPRESSANT. RENEWAL CRITERIA: DOCUMENTATION OF A POSITIVE RESPONSE.

Age Restriction

RESERVED FOR PATIENTS AGE 18 AND OLDER.

Prescriber Restriction

RESERVED FOR PRESCRIBING BY NEUROLOGY.

Coverage Duration

SIX MONTHS, THEN BALANCE OF CONTRACT YEAR IF RENEWAL CRITERIA ARE MET.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

ANDROGEN THERAPY

Drugs

testosterone cypionate, testosterone enanthate, testosterone transdermal gel in metered-dose pump, testosterone transdermal gel in packet

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

(1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) DOCUMENTED TESTOSTERONE DEFICIENCY IN MALES OF LESS THAN 300 NG/DL.

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

ANTICONVULSANTS - SELECT AGENTS

Drugs

APTIOM, BANZEL ORAL SUSPENSION, BANZEL ORAL TABLET 200 MG, 400 MG, FYCOMPA ORAL SUSPENSION, FYCOMPA ORAL TABLET

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

FOR NEW START PATIENTS: DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY NEUROLOGY.

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

ANTIDEPRESSANTS - NON-PREFERRED AGENTS

Drugs

FETZIMA, TRINTELLIX, VIIBRYD ORAL TABLET, VIIBRYD ORAL TABLETS, DOSE PACK 10 MG (7)- 20 MG (23)

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

FOR NEW START PATIENTS: (1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) DOCUMENTATION OF AN INADEQUATE RESPONSE OR MEDICAL CONTRAINDICATION TO TWO PREFERRED ALTERNATIVE ANTIDEPRESSANTS, SUCH AS: CITALOPRAM, ESCITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE, VENLAFAXINE, OR DULOXETINE.

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

ANTINEOPLASTIC INJECTABLES

Drugs

ABRAXANE, **ALIMTA**, **ALIQOPA**, *amifostine crystalline*, **ARRANON**, *arsenic trioxide*, **ARZERRA**, **AVASTIN**, *azacitidine*, **BAVENCIO**, **BELEODAQ**, **BENDEKA**, **BESPONSA**, **BICNU**, **BLINCYTO INTRAVENOUS KIT**, **BORTEZOMIB**, *busulfan*, **CAMPTOSAR INTRAVENOUS SOLUTION 300 MG/15 ML**, *carboplatin intravenous solution*, *carmustine*, *cisplatin*, *clofarabine*, **CYRAMZA**, *dacarbazine*, *dactinomycin*, **DARZALEX**, *daunorubicin*, *decitabine*, *docetaxel intravenous solution 160 mg/8 ml (20 mg/ml)*, *20 mg/2 ml (10 mg/ml)*, *20 mg/ml*, *20 mg/ml (1 ml)*, *80 mg/4 ml (20 mg/ml)*, *80 mg/8 ml (10 mg/ml)*, **EMPLICITI**, *epirubicin*, **ERBITUX**, **ERWINAZE**, **FASLODEX**, *fludarabine*, **FOLOTYN**, **GAZYVA**, *gemcitabine*, **HALAVEN**, **HERCEPTIN**, *idarubicin*, *ifosfamide*, **IMFINZI**, *irinotecan*, **IXEMPRA**, **JEVTANA**, **KADCYLA**, **KEYTRUDA INTRAVENOUS SOLUTION**, **KYPROLIS**, **LARTRUVO**, **LIBTAYO**, **LUMOXITI**, **LUPRON DEPOT**, **LUPRON DEPOT (3 MONTH)**, **LUPRON DEPOT (4 MONTH)**, **LUPRON DEPOT (6 MONTH)**, *melfhalan hcl*, *mitomycin intravenous*, *mitoxantrone*, **MUSTARGEN**, *mutamycin*, **MYLOTARG**, **ONCASPAR**, **ONIVYDE**, **OPDIVO**, *oxaliplatin*, *paclitaxel*, **PERJETA**, **PORTRAZZA**, **POTELIGEO**, **PROLEUKIN**, **RITUXAN HYCELA**, *romidepsin*, **SYLVANT**, **TECENTRIQ**, **TEMODAR INTRAVENOUS**, *temsirolimus*, *thiotepa*, **TORISEL**, **TREANDA INTRAVENOUS RECON SOLN**, **TRELSTAR**, **TRISENOX INTRAVENOUS SOLUTION 2 MG/ML**, **UNITUXIN**, **UVADEX**, **VECTIBIX**, **VELCADE**, *vincasar pfs*, *vincristine*, *vinorelbine*, **VYXEOS**, **YERVOY**, **ZANOSAR**

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

INITIAL: FOR NEW START PATIENTS: (1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, OR (2) DOCUMENTATION THAT A PATIENT IS CURRENTLY RECEIVING OR HAS PREVIOUSLY RECEIVED AND BENEFITED FROM THE USE OF THIS MEDICATION FOR THE TREATMENT OF CANCER. RENEWAL: DOCUMENTATION OF A BENEFICIAL RESPONSE.

Age Restriction

Prescriber Restriction

Coverage Duration

SIX MONTHS, THEN BALANCE OF CONTRACT YEAR IF RENEWAL CRITERIA ARE MET.

Other Criteria

ANTINEOPLASTIC INJECTABLES WITH BVD

Drugs

bleomycin, cladribine, cytarabine, cytarabine (pf) injection solution 100 mg/5 ml (20 mg/ml), 2 gram/20 ml (100 mg/ml), doxorubicin intravenous solution, doxorubicin, peg-liposomal, fluorouracil intravenous solution 1 gram/20 ml, 5 gram/100 ml, 500 mg/10 ml, IMLYGIC, vinblastine intravenous solution, YONDELIS

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

INITIAL: FOR NEW START PATIENTS: (1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, OR (2) DOCUMENTATION THAT A PATIENT IS CURRENTLY RECEIVING OR HAS PREVIOUSLY RECEIVED AND BENEFITED FROM THE USE OF THIS MEDICATION FOR THE TREATMENT OF CANCER. RENEWAL: DOCUMENTATION OF A BENEFICIAL RESPONSE.

Age Restriction

Prescriber Restriction

Coverage Duration

SIX MONTHS, THEN BALANCE OF CONTRACT YEAR IF RENEWAL CRITERIA ARE MET.

Other Criteria

THIS DRUG MAY BE COVERED UNDER MEDICARE PART B OR PART D DEPENDING ON THE CIRCUMSTANCES. INFORMATION MAY NEED TO BE SUBMITTED DESCRIBING THE USE OF THE DRUG AND SETTING WHERE THE DRUG IS DISPENSED TO MAKE THE PART B OR PART D COVERAGE DETERMINATION.

ANTIPARKINSON AGENTS

Drugs

NEUPRO

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

(1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) DOCUMENTATION OF SIGNIFICANT SIDE EFFECTS, LOSS OF EFFICACY, OR COMPLIANCE CONCERNS WITH REGULAR RELEASE PRAMIPEXOLE OR ROPINIROLE.

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

ATYPICAL ANTIPSYCHOTIC AGENTS

Drugs

FANAPT, *paliperidone*, REXULTI, SAPHRIS, SAPHRIS (BLACK CHERRY), VRAYLAR

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

FOR NEW START PATIENTS: (1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) DOCUMENTATION OF AN INADEQUATE RESPONSE OR MEDICAL CONTRAINDICATION TO TWO OF THE FOLLOWING ALTERNATIVES: RISPERIDONE, ZIPRASIDONE, OLANZAPINE, QUETIAPINE REGULAR RELEASE, QUETIAPINE EXTENDED RELEASE OR ARIPIPRAZOLE.

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

AUSTEDO

Drugs

AUSTEDO

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY NEUROLOGY OR PSYCHIATRY.

Coverage Duration

THREE MONTHS, THEN BALANCE OF CONTRACT YEAR IF POSITIVE RESPONSE.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

BETASERON

Drugs

BETASERON SUBCUTANEOUS KIT

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

(1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) DOCUMENTATION OF INADEQUATE RESPONSE OR MEDICAL CONTRAINDICATION TO EXTAVIA.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY NEUROLOGY

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

BRIVIACT

Drugs

BRIVIACT

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

FOR NEW START PATIENTS: (1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) DOCUMENTATION OF AN INADEQUATE RESPONSE OR MEDICAL CONTRAINDICATION TO LEVETIRACETAM AND ONE ADDITIONAL PREFERRED SEIZURE MEDICATION, SUCH AS LAMOTRIGINE, CARBAMAZEPINE, DIVALPROEX, PHENYTOIN, TOPIRAMATE.

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

Drugs

CIMZIA, CIMZIA POWDER FOR RECONST

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

MAY NOT USE CIMZIA CONCURRENTLY WITH OTHER BIOLOGIC THERAPIES.

Required Medical Information

INITIAL CRITERIA: (1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) MEDICAL CHART DOCUMENTATION OF BASELINE DISEASE ACTIVITY AND/OR FUNCTIONAL ASSESSMENT AND TREATMENT GOALS, (3) FOR RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS, AND PLAQUE PSORIASIS: DOCUMENTATION OF MEDICAL CONTRAINDICATIONS OR INADEQUATE RESPONSE WITH ENBREL AND HUMIRA, OR FOR CROHN'S DISEASE: DOCUMENTATION OF MEDICAL CONTRAINDICATION OR INADEQUATE RESPONSE TO HUMIRA. RENEWAL CRITERIA: MEDICAL CHART DOCUMENTATION THAT TREATMENT GOALS HAVE BEEN MET FOR THERAPY.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY RHEUMATOLOGY, DERMATOLOGY, OR GASTROENTEROLOGY WITHIN THE SCOPE OF THE APPLICABLE PRESCRIBER SPECIALTY.

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

CLOMIPRAMINE

Drugs

clomipramine

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

FOR NEW START PATIENTS: DIAGNOSIS OF OBSESSIVE-COMPULSIVE DISORDER, OR DOCUMENTATION THAT THE PATIENT IS MONITORED FOR ADVERSE DRUG EVENTS.

Age Restriction

RESTRICTIONS APPLY TO PATIENTS GREATER THAN 64 YEARS OF AGE.

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

CLONIDINE EXTENDED RELEASE

Drugs

clonidine hcl oral tablet extended release 12 hr

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

(1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) DOCUMENTED FAILURE WITH STANDARD GENERIC ADHD MEDICATIONS SUCH AS METHYLPHENIDATE OR DEXTROAMPHETAMINE-AMPHETAMINE COMBINATION.

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

COPAXONE 20MG

Drugs

COPAXONE SUBCUTANEOUS SYRINGE 20 MG/ML

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

(1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) DOCUMENTATION OF INADEQUATE RESPONSE OR MEDICAL CONTRAINDICATION TO GLATOPA 20MG OR GLATIRAMER 20MG.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY NEUROLOGY

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

COPAXONE 40MG

Drugs

COPAXONE SUBCUTANEOUS SYRINGE 40 MG/ML

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

(1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) DOCUMENTATION OF INADEQUATE RESPONSE OR MEDICAL CONTRAINDICATION TO GLATIRAMER 40MG.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY NEUROLOGY

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

COSENTYX

Drugs

COSENTYX (2 SYRINGES), COSENTYX PEN (2 PENS)

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

MAY NOT USE COSENTYX CONCURRENTLY WITH OTHER BIOLOGIC THERAPIES.

Required Medical Information

INITIAL: (1) MEDICAL CHART DOCUMENTATION OF TREATMENT GOALS AND BASELINE DISEASE ACTIVITY/FUNCTIONAL ASSESSMENT, AND (2) DIAGNOSIS OF: (A) MODERATE TO SEVERE PLAQUE PSORIASIS (AT LEAST 5% BODY SURFACE AREA, OR PRESENTATION IN PALMAR, PLANTAR, FACIAL, SCALP, AND/OR GENITAL REGIONS, PUSTULAR PSORIASIS), OR (B) ANKYLOSING SPONDYLITIS, OR (C) PSORIATIC ARTHRITIS, AND (3) MEDICAL CHART DOCUMENTATION OF CONTRAINDICATIONS OR INADEQUATE RESPONSE TO BOTH ENBREL AND HUMIRA. RENEWAL CRITERIA: MEDICAL CHART DOCUMENTATION THAT TREATMENT GOALS HAVE BEEN MET FOR THERAPY.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY DERMATOLOGY AND RHEUMATOLOGY WITHIN THE SCOPE OF THE APPLICABLE PRESCRIBER SPECIALTY

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

CYSTARAN

Drugs

CYSTARAN

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

INITIAL CRITERIA: DIAGNOSIS OF CYSTINOSIS. RENEWAL CRITERIA: DOCUMENTATION OF CLINICAL TREATMENT EFFECT (SUCH AS DOCUMENTATION OF SLIT LAMP EXAM RESULTS)

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY PROVIDERS SPECIALIZING IN GENETICS AND METABOLISM, OR FOR OPHTHALMOLOGY SPECIALISTS.

Coverage Duration

THREE MONTHS, THEN BALANCE OF CONTRACT YEAR IF RENEWAL CRITERIA ARE MET.

Other Criteria

DAKLINZA

Drugs **DAKLINZA**

Covered Uses

ALL FDA-APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

(1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, (2) DOCUMENTATION OF HEPATITIS C GENOTYPE AND BASELINE VIRAL LOAD, PROVIDER ATTESTATION OF READINESS TO TREAT, PATIENT ATTESTATION OF READINESS FOR TREATMENT, AND SUBMISSION OF VIROLOGIC RESPONSE UPON COMPLETION OF TREATMENT, AND (3) DOCUMENTED CLINICAL INAPPROPRIATENESS OF OR INABILITY TO TOLERATE HARVONI, EPCLUSA, OR MAVYRET REGIMENS.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY GASTROENTEROLOGY, OR HEPATOLOGY, OR INFECTIOUS DISEASE SPECIALISTS.

Coverage Duration

DURATION PER GENOTYPE AND DIAGNOSIS. 12-24 WEEKS PER FDA APPROVED LABELING OR CLINICAL GUIDELINES.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

DALFAMPRIDINE ER

Drugs

dalfampridine

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

INITIAL CRITERIA: (1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, (2) DOCUMENTATION THAT THE PATIENT IS CURRENTLY ABLE TO WALK 25 FEET, AND (3) PHYSICIAN ATTESTATION THAT PATIENT HAS DIFFICULTY WALKING. RENEWAL CRITERIA: DOCUMENTATION OF A POSITIVE RESPONSE.

Age Restriction

Prescriber Restriction

Coverage Duration

SIX MONTHS, THEN BALANCE OF CONTRACT YEAR IF POSITIVE RESPONSE.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

DALIRESP

Drugs

DALIRESP

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

(1) DIAGNOSIS OF SEVERE COPD CONFIRMED WITH AN FEV-1 LESS THAN 50 PERCENT OF PREDICTED, AND (2) ASSOCIATED CHRONIC BRONCHITIS AS DEFINED BY THE PRESENCE OF COUGH AND SPUTUM PRODUCTION FOR AT LEAST 3 MONTHS IN EACH OF TWO CONSECUTIVE YEARS, AND (3) DOCUMENTATION OF INADEQUATE RESPONSE OR MEDICAL CONTRAINDICATIONS TO TWO OF THE FOLLOWING: LONG-ACTING BETA-AGONIST (SUCH AS FORMOTEROL OR SALMETEROL), ANTICHOLINERGIC (SUCH AS IPRATROPIUM) OR ORAL INHALED STEROID (SUCH AS BECLOMETHASONE, BUDESONIDE, FLUTICASONE OR MOMETASONE).

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

DESVENLAFAXINE

Drugs

desvenlafaxine succinate

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

FOR NEW START PATIENTS: (1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) DOCUMENTATION OF AN INADEQUATE RESPONSE TO VENLAFAXINE ER AND DULOXETINE.

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

DIFICID

Drugs DIFICID

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

(1) DIAGNOSIS OF CLOSTRIDIUM DIFFICILE INFECTION, AND (2) DOCUMENTATION OF AN INADEQUATE RESPONSE OR MEDICAL CONTRAINDICATION TO METRONIDAZOLE AND VANCOMYCIN.

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

DIGOXIN

Drugs

digitek oral tablet 250 mcg, digox oral tablet 250 mcg, digoxin oral tablet 250 mcg

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

(1) THE PATIENT IS CURRENTLY STABLE ON DIGOXIN 0.25 MG AND IS MONITORED FOR ADVERSE DRUG EVENTS, OR (2) FOR PATIENTS WITH ATRIAL FIBRILLATION AND CONTRAINDICATIONS OR INADEQUATE RESPONSE TO COMBINATION THERAPY WITH A LOWER DOSE OF DIGOXIN AND EITHER A BETA BLOCKER OR A NON DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER (SUCH AS DILTIAZEM OR VERAPAMIL), OR (3) FOR PATIENTS WITH HEART FAILURE AND CONTRAINDICATIONS OR INADEQUATE RESPONSE TO COMBINATION THERAPY WITH A LOWER DOSE OF DIGOXIN AND A BETA BLOCKER.

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

DIHYDROERGOTAMINE

Drugs

dihydroergotamine

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

(1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) DOCUMENTATION OF MEDICAL CONTRAINDICATIONS OR INADEQUATE RESPONSE WITH TWO TRIPTAN MEDICATIONS SUCH AS SUMATRIPTAN, NARATRIPTAN OR RIZATRIPTAN.

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

DULERA

Drugs

DULERA

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

(1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) DOCUMENTATION OF FAILURE WITH ADVAIR.

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

DUPIXENT

Drugs DUPIXENT

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

(1) MEDICAL CHART DOCUMENTATION OF MODERATE TO SEVERE ATOPIC DERMATITIS WITH AT LEAST 10% BODY SURFACE AREA (BSA) OR INVOLVEMENT WITH THE FACE, NECK, HANDS, FEET, OR GENITALS, AND (2) DOCUMENTATION OF MEDICAL CONTRAINDICATIONS OR INADEQUATE RESPONSE TO ONE PRESCRIPTION-STRENGTH TOPICAL CORTICOSTEROID.

Age Restriction

RESERVED FOR PATIENTS AGE 18 AND OLDER.

Prescriber Restriction

RESERVED FOR PRESCRIBING BY AN ALLERGIST, IMMUNOLOGIST, OR DERMATOLOGIST.

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

EMSAM

Drugs EMSAM

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

FOR NEW START PATIENTS: (1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) DOCUMENTATION OF AN INADEQUATE RESPONSE OR MEDICAL CONTRAINDICATION TO ONE PREFERRED DRUG FROM EACH OF THE FOLLOWING TWO ANTIDEPRESSANT SUB-CLASSES: (A) SSRI'S SUCH AS CITALOPRAM, ESCITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE, AND (B) SNRI'S SUCH AS VENLAFAXINE OR DULOXETINE.

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

Drugs

ENBREL, ENBREL SURECLICK

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

MAY NOT USE ENBREL CONCURRENTLY WITH OTHER BIOLOGIC THERAPIES.

Required Medical Information

INITIAL: (1) DOCUMENTATION OF TREATMENT GOALS AND BASELINE DISEASE ACTIVITY/FUNCTIONAL ASSESSMENT, AND (2) DIAGNOSIS OF: (A) RHEUMATOID ARTHRITIS W/DOCUMENTATION OF CONTRAINDICATION/INTOLERANCE TO/FAILURE (C/I/F) W/CONCURRENT USE OF 2 OF THE FOLLOWING FOR 3 MOS: METHOTREXATE, HYDROXYCHLOROQUINE, LEFLUNOMIDE, OR SULFASALAZINE, OR (B) JUVENILE IDIOPATHIC ARTHRITIS OR PSORIATIC ARTHRITIS W/DOCUMENTATION OF C/I/F TO BOTH OF THE FOLLOWING FOR 1 MONTH: CONTINUOUS TREATMENT WITH ONE NSAID AND METHOTREXATE, OR (C) ANKYLOSING SPONDYLITIS WITH DOCUMENTATION OF C/I/F TO CONTINUOUS TREATMENT WITH ONE NSAID FOR 1 MONTH, AND FOR PERIPHERAL DISEASE ONLY, DOCUMENTATION OF C/I/F W/ONE OF THE FOLLOWING: CONTINUOUS LOCAL CORTICOSTEROID INJECTION THERAPY (WHEN DISEASE PROCESS PERMITS), METHOTREXATE, OR SULFASALAZINE, OR (D) PLAQUE PSORIASIS W/AT LEAST 5% BODY SURFACE AREA, OR PRESENTATION IN PALMAR, PLANTAR, FACIAL, SCALP, AND/OR GENITAL REGIONS, OR PUSTULAR PSORIASIS, W/DOCUMENTATION OF C/I/F TO 2 OF THE FOLLOWING FOR 3 MOS: TOPICAL CORTICOSTEROID THERAPY, PHOTOTHERAPY, METHOTREXATE, CYCLOSPORINE, ACITRETIN. RENEWAL: DOCUMENTATION TREATMENT GOALS HAVE BEEN MET.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY DERMATOLOGY AND RHEUMATOLOGY WITHIN THE SCOPE OF THE APPLICABLE PRESCRIBER SPECIALTY.

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

ENZYME REPLACEMENT

Drugs

ADAGEN, ALDURAZYME, CERDELGA, CHOLBAM, ELAPRASE, ELELYSO, ELITEK, FABRAZYME, ILARIS (PF) SUBCUTANEOUS SOLUTION, LUMIZYME, NAGLAZYME, ORFADIN, VPRIV

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY PROVIDERS SPECIALIZING IN GENETICS AND METABOLISM, GASTROENTEROLOGY, HEMATOLOGY, AND NEPHROLOGY WITHIN THE SCOPE OF THE APPLICABLE PRESCRIBER SPECIALTY.

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

EPCLUSA

Drugs

EPCLUSA, *sofosbuvir-velpatasvir*

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

(1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) DOCUMENTATION OF HEPATITIS C GENOTYPE AND BASELINE VIRAL LOAD, PROVIDER ATTESTATION OF READINESS TO TREAT, PATIENT ATTESTATION OF READINESS FOR TREATMENT, AND SUBMISSION OF VIROLOGIC RESPONSE UPON COMPLETION OF TREATMENT.

Age Restriction

RESERVED FOR PATIENTS AGE 18 AND OLDER.

Prescriber Restriction

RESERVED FOR PRESCRIBING BY GASTROENTEROLOGY, HEPATOLOGY, INFECTIOUS DISEASE SPECIALISTS, OR TRANSPLANT SPECIALIST.

Coverage Duration

DURATION PER GENOTYPE AND DIAGNOSIS. 12 WEEKS PER FDA APPROVED LABELING OR CLINICAL GUIDELINES.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

ERYTHROPOIESIS STIMULATING AGENTS

Drugs

ARANESP (IN POLYSORBATE), PROCRIT, RETACRIT

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

PATIENT MUST NOT HAVE AN FDA-LABELED LIMITATION OF USE OR CONTRAINDICATION TO THERAPY.

Required Medical Information

(1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) FOR CANCER DIAGNOSIS: DOCUMENTED CHEMOTHERAPY-ASSOCIATED ANEMIA (HEMOGLOBIN LESS THAN 10G/DL OR HEMATOCRIT LESS THAN 30%).

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

THIS DRUG MAY BE COVERED UNDER MEDICARE PART B OR PART D DEPENDING ON THE CIRCUMSTANCES. INFORMATION MAY NEED TO BE SUBMITTED DESCRIBING THE USE OF THE DRUG AND SETTING WHERE THE DRUG IS DISPENSED TO MAKE THE PART B OR PART D COVERAGE DETERMINATION.

EUCRISA

Drugs EUCRISA

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

(1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) DOCUMENTATION OF MEDICAL CONTRAINDICATIONS OR INADEQUATE RESPONSE TO ONE PRESCRIPTION-STRENGTH TOPICAL CORTICOSTEROID.

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

FAMOTIDINE INJECTION

Drugs

famotidine (pf), famotidine intravenous solution

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

(1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) DOCUMENTATION OF: (A) FAILURE WITH ORAL FORMULARY HISTAMINE 2 RECEPTOR ANTAGONISTS FAMOTIDINE AND RANITIDINE, OR (B) MEDICAL CONTRAINDICATIONS TO ORAL HISTAMINE 2 RECEPTOR ANTAGONISTS.

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

FDA-APPROVED INDICATIONS

Drugs

ABILIFY MAINTENA, *amikacin injection solution 1,000 mg/4 ml, 500 mg/2 ml*, **ANADROL-50**, **APOKYN**, **ARALAST NP INTRAVENOUS RECON SOLN 1,000 MG**, **ARISTADA**, **ARISTADA INITIO**, **ATGAM**, **BENLYSTA**, **BERINERT INTRAVENOUS KIT**, **CAPASTAT**, *casprofungin*, **CAYSTON**, *chloramphenicol sod succinate*, **CHORIONIC GONADOTROPIN, HUMAN**, **CINRYZE**, **CORLANOR**, *cycloserine*, *daptomycin*, **DEMSER**, *dexrazoxane hcl*, **EPIDIOLEX**, **ERAXIS(WATER DILUENT)**, **FIRAZYR**, *fomepizole*, **GLASSIA**, **HAEGARDA**, **HETLIOZ**, **INVEGA SUSTENNA**, **INVEGA TRINZA**, **KALBITOR**, **KEPIVANCE**, **KHAPZORY**, **KORLYM**, **KRYSTEXXA**, **LEVOLEUCOVORIN CALCIUM INTRAVENOUS RECON SOLN 175 MG**, *levoleuovorin calcium intravenous recon soln 50 mg, levoleuovorin calcium intravenous solution*, **LUPRON DEPOT-PED (3 MONTH) INTRAMUSCULAR SYRINGE KIT 30 MG**, **LUPRON DEPOT-PED INTRAMUSCULAR KIT 11.25 MG, 15 MG**, *mesna*, **MOVANTIK**, **MOZOBIL**, **NUPLAZID**, *oxandrolone oral tablet 10 mg, 2.5 mg*, **PERSERIS**, **PROLASTIN-C INTRAVENOUS RECON SOLN**, *quinine sulfate*, **RANEXA**, *rifampin intravenous*, **RUCONEST**, **SIRTURO**, *sodium phenylbutyrate oral tablet*, **SOLIRIS**, **SOMATULINE DEPOT SUBCUTANEOUS SYRINGE 120 MG/0.5 ML, 60 MG/0.2 ML, 90 MG/0.3 ML**, **SOMAVERT**, **SYMPROIC**, **SYNAGIS**, **SYNAREL**, **TAKHZYRO**, **TARGRETIN TOPICAL**, **TOBI PODHALER INHALATION CAPSULE, W/INHALATION DEVICE**, *tobramycin sulfate injection solution*, *tranexamic acid intravenous*, **VISTOGARD**, **XYREM**, **ZEMAIRA**, **ZORBTIVE**, **ZYPREXA RELPREVV**

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D.

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

FDA-APPROVED INDICATIONS - DOSE LIMIT

Drugs

STRENSIQ

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D.

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

FDA-APPROVED INDICATIONS WITH BVD

Drugs

ABELCET, AMBISOME, *amphotericin b*, BIVIGAM, CARIMUNE NF NANOFILTERED INTRAVENOUS RECON SOLN 12 GRAM, 6 GRAM, CUVITRU, FLEBOGAMMA DIF, *foscarnet*, GAMASTAN S/D, GAMMAGARD LIQUID, GAMMAGARD S-D (IGA < 1 MCG/ML), GAMMAKED, GAMMAPLEX, GAMMAPLEX (WITH SORBITOL), GAMUNEX-C, HIZENTRA, HYQVIA, OCTAGAM, PRIVIGEN, PULMOZYME, *tobramycin in 0.225 % nacl*, ZORTRESS

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D.

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

THIS DRUG MAY BE COVERED UNDER MEDICARE PART B OR PART D DEPENDING ON THE CIRCUMSTANCES. INFORMATION MAY NEED TO BE SUBMITTED DESCRIBING THE USE OF THE DRUG AND SETTING WHERE THE DRUG IS DISPENSED TO MAKE THE PART B OR PART D COVERAGE DETERMINATION.

FONDAPARINUX

Drugs

fondaparinux

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D, DIAGNOSIS OF HEPARIN-INDUCED THROMBOCYTOPENIA, AND DIAGNOSIS OF MALIGNANCY WITH HYPERCOAGULABLE STATE.

Exclusion Criteria

Required Medical Information

(1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND DOCUMENTATION OF FAILURE OR MEDICAL CONTRAINDICATIONS WITH ENOXAPARIN, OR (2) DIAGNOSIS OF HEPARIN-INDUCED THROMBOCYTOPENIA, OR (3) DIAGNOSIS OF MALIGNANCY WITH HYPERCOAGULABLE STATE.

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

FORTEO

Drugs

FORTEO

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

(1) DIAGNOSIS OF: (A) FRAGILITY FRACTURE OF THE SPINE OR HIP WITHIN THE LAST FIVE YEARS, OR (B) SEVERE OSTEOPOROSIS WITH A T-SCORE OF SPINE, HIP OR FEMORAL NECK OF MINUS 3.5 OR LOWER, OR (C) OSTEOPOROSIS WITH A T-SCORE OF MINUS 2.5 OR LOWER AND (I) INTOLERANCE OR CONTRAINDICATION TO BISPHOSPHONATE THERAPY, OR (II) PROGRESSIVE BONE LOSS DEFINED AS BONE LOSS OF THREE PERCENT OR HIGHER DESPITE THERAPY WITH BISPHOSPHONATES, ADEQUATE CALCIUM INTAKE AND VITAMIN D INTAKE WITH VITAMIN D SERUM LEVELS OF 30 NG/ML OR HIGHER, AND (2) DOCUMENTED FAILURE OF, INTOLERANCE TO, OR CONTRAINDICATIONS TO TYMLOS.

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

FULYZAQ

Drugs

MYTESI

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

INITIAL CRITERIA: DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND CONTRAINDICATIONS OR INADEQUATE RESPONSE TO LOPERAMIDE AND DIPHENOXYLATE/ATROPINE. RENEWAL CRITERIA: DOCUMENTATION OF BENEFICIAL RESPONSE.

Age Restriction

Prescriber Restriction

Coverage Duration

THREE MONTHS, THEN BALANCE OF CONTRACT YEAR IF RENEWAL CRITERIA ARE MET.

Other Criteria

GALAFOLD

Drugs

GALAFOLD

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D.

Age Restriction

RESERVED FOR PATIENTS AGE 18 AND OLDER.

Prescriber Restriction

RESERVED FOR PRESCRIBING BY PROVIDERS SPECIALIZING IN GENETICS AND METABOLISM, GASTROENTEROLOGY, HEMATOLOGY, AND NEPHROLOGY WITHIN THE SCOPE OF THE APPLICABLE PRESCRIBER SPECIALTY.

Coverage Duration

SIX MONTHS, THEN BALANCE OF CONTRACT YEAR IF RENEWAL CRITERIA ARE MET.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

GATTEX

Drugs

GATTEX 30-VIAL

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

INITIAL CRITERIA: (1) TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME, AND (2) WHO HAVE BEEN DEPENDENT ON PARENTERAL (OR A COMBINATION OF PARENTERAL AND ENTERAL) NUTRITION FOR ALL NUTRITIONAL REQUIREMENTS FOR AT LEAST ONE YEAR, AND (3) IN WHOM A TAPER FROM PARENTERAL REQUIREMENTS HAS NOT BEEN POSSIBLE OR PLANNED. RENEWAL CRITERIA: MEDICAL RECORD DOCUMENTATION OF POSITIVE RESPONSE.

Age Restriction

Prescriber Restriction

Coverage Duration

THREE MONTHS, THEN BALANCE OF CONTRACT YEAR IF RENEWAL CRITERIA ARE MET.

Other Criteria

DOSE IS LIMITED TO THE FDA-APPROVED DOSE OF 0.05 MG/KG PER DAY.

HARVONI

Drugs

HARVONI, *ledipasvir-sofosbuvir*

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

(1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) DOCUMENTATION OF HEPATITIS C GENOTYPE AND BASELINE VIRAL LOAD, PROVIDER ATTESTATION OF READINESS TO TREAT, PATIENT ATTESTATION OF READINESS FOR TREATMENT, AND SUBMISSION OF VIROLOGIC RESPONSE UPON COMPLETION OF TREATMENT.

Age Restriction

RESERVED FOR PATIENTS AGE 12 AND OLDER.

Prescriber Restriction

RESERVED FOR PRESCRIBING BY GASTROENTEROLOGY, HEPATOLOGY, INFECTIOUS DISEASE SPECIALISTS, OR TRANSPLANT SPECIALIST.

Coverage Duration

12-24 WKS PER DIAGNOSIS, FDA LABELING OR CLINICAL GUIDELINES. 8 WK APPROVALS PER PROVIDER REQUEST.

Other Criteria

DOSE IS LIMITED TO THE FDA-APPROVED REGIMEN OF ONE TABLET DAILY.

HIGH-STRENGTH OPIOID AGENTS

Drugs

buprenorphine, fentanyl transdermal patch 72 hour 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr, methadone oral concentrate, methadone oral solution, methadone oral tablet, morphine oral tablet extended release 15 mg, 30 mg, 60 mg

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

(1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) PROVIDER ATTESTATION OF INTENT TO MONITOR FOR SIDE EFFECTS AND APPROPRIATE USE.

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AGENTS

Drugs

JUXTAPID, KYNAMRO

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

INITIAL: (1) CONFIRMED DIAGNOSIS OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, AND (2) THERAPEUTIC FAILURE, INTOLERANCE, OR CONTRAINDICATION TO ONE HIGH-INTENSITY STATIN THERAPY AND TO ONE PCSK9-INHIBITOR (SUCH AS REPATHA). RENEWAL: DOCUMENTATION OF BENEFICIAL RESPONSE.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY CARDIOLOGY AND ENDOCRINOLOGY.

Coverage Duration

THREE MONTHS, THEN BALANCE OF CONTRACT YEAR IF RENEWAL CRITERIA ARE MET.

Other Criteria

HUMIRA

Drugs

HUMIRA, HUMIRA PEDIATRIC CROHNS START, HUMIRA PEN, HUMIRA PEN CROHNS-UC-HS START, HUMIRA PEN PSOR-UVEITS-ADOL HS, HUMIRA(CF), HUMIRA(CF) PEDI CROHNS STARTER, HUMIRA(CF) PEN, HUMIRA(CF) PEN CROHNS-UC-HS, HUMIRA(CF) PEN PSOR-UV-ADOL HS

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

MAY NOT USE HUMIRA CONCURRENTLY WITH OTHER BIOLOGIC THERAPIES.

Required Medical Information

INITIAL: (1) DOCUMENTATION OF TREATMENT GOALS AND BASELINE DISEASE ACTIVITY/FUNCTIONAL ASSESSMENT, AND (2) DIAGNOSIS OF: (A) RHEUMATOID ARTHRITIS W/DOCUMENTATION OF CONTRAINDICATION/INTOLERANCE TO/FAILURE (C/I/F) W/CONCURRENT USE OF 2 OF THE FOLLOWING FOR 3 MOS: METHOTREXATE, HYDROXYCHLOROQUINE, LEFLUNOMIDE, OR SULFASALAZINE, OR (B) JUVENILE IDIOPATHIC ARTHRITIS OR PSORIATIC ARTHRITIS W/DOCUMENTATION OF C/I/F TO BOTH OF THE FOLLOWING FOR 1 MONTH: CONTINUOUS TREATMENT WITH ONE NSAID AND METHOTREXATE, OR (C) ANKYLOSING SPONDYLITIS W/DOCUMENTATION OF C/I/F TO CONTINUOUS TREATMENT WITH ONE NSAID FOR 1 MONTH, AND FOR PERIPHERAL DISEASE ONLY, DOCUMENTATION OF C/I/F W/ONE OF THE FOLLOWING: CONTINUOUS LOCAL CORTICOSTEROID INJECTION THERAPY (WHEN DISEASE PROCESS PERMITS), METHOTREXATE, OR SULFASALAZINE, OR (D) PLAQUE PSORIASIS W/AT LEAST 5% BODY SURFACE AREA, OR PRESENTATION IN PALMAR, PLANTAR, FACIAL, SCALP, AND/OR GENITAL REGIONS, OR PUSTULAR PSORIASIS, W/DOCUMENTATION OF C/I/F TO 2 OF THE FOLLOWING FOR 3 MOS: TOPICAL CORTICOSTEROID THERAPY, PHOTOTHERAPY, METHOTREXATE, CYCLOSPORINE, ACITRETIN, OR (E) MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE W/: (I) FISTULIZING DISEASE, OR (II) DOCUMENTATION OF C/I/F TO 1 OF THE FOLLOWING: PREDNISONE OR BUDESONIDE FOR 14 DAYS, OR AZATHIOPRINE, 6-MERCAPTOPYRINE, OR METHOTREXATE FOR 3 MOS, OR (F) MODERATE TO SEVERELY ACTIVE ULCERATIVE COLITIS W/DOCUMENTATION OF C/I/F TO 2 OF THE FOLLOWING FOR 3 MOS: SULFASALAZINE, MESALAMINE, BALSALAZIDE, PREDNISONE, BUDESONIDE, AZATHIOPRINE, 6-MERCAPTOPYRINE, OR (G) HIDRADENITIS SUPPURATIVA, OR (H) NON-INFECTIOUS INTERMEDIATE, POSTERIOR AND PANUVEITIS. RENEWAL: DOCUMENTATION TREATMENT GOALS HAVE BEEN MET.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY DERMATOLOGY, GASTROENTEROLOGY, OPHTHALMOLOGY, AND RHEUMATOLOGY WITHIN THE SCOPE OF THE APPLICABLE PRESCRIBER SPECIALTY.

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

IDIOPATHIC PULMONARY FIBROSIS AGENTS

Drugs

ESBRIET, OFEV

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY PULMONOLOGY

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES

INFECTIOUS DISEASE SELECT AGENTS

Drugs

CRESEMBA ORAL, *linezolid*, *linezolid in dextrose 5%*, **NOXAFIL ORAL**, **SIVEXTRO**, *voriconazole*

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY OR IN CONSULTATION WITH AN INFECTIOUS DISEASE SPECIALIST.

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

INGREZZA

Drugs INGREZZA

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

INITIAL CRITERIA: (1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) MEDICAL CHART DOCUMENTATION OF FUNCTIONAL IMPAIRMENT DUE TO MODERATE-TO-SEVERE TARDIVE DYSKINESIA SYMPTOMS. RENEWAL CRITERIA: (1) DOCUMENTATION THAT THE PATIENT HAS BEEN SEEN WITHIN THE LAST 12 MONTHS, AND (2) DOCUMENTATION OF EFFECTIVENESS.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY NEUROLOGY OR PSYCHIATRY.

Coverage Duration

THREE MONTHS, THEN BALANCE OF CONTRACT YEAR IF POSITIVE RESPONSE.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

ITRACONAZOLE

Drugs

itraconazole, **SPORANOX ORAL SOLUTION**

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

(1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) FOR COMPLEX FUNGAL NAIL INFECTIONS (ONYCHOMYCOSIS): DOCUMENTED FAILURE ON ORAL TERBINAFINE.

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

KALYDECO

Drugs

KALYDECO, ORKAMBI, SYMDEKO

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

PATIENT MUST NOT HAVE AN FDA-LABELED LIMITATION OF USE OR CONTRAINDICATION TO THERAPY.

Required Medical Information

INITIAL CRITERIA: (1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D. RENEWAL CRITERIA: (1) DOCUMENTATION THAT THE PATIENT HAS BEEN SEEN WITHIN THE LAST 12 MONTHS, AND (2) DOCUMENTATION OF EFFECTIVENESS.

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

KEVZARA

Drugs

KEVZARA

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

MAY NOT USE KEVZARA CONCURRENTLY WITH OTHER BIOLOGIC THERAPIES.

Required Medical Information

INITIAL CRITERIA: (1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) DOCUMENTATION OF MEDICAL CONTRAINDICATIONS OR INADEQUATE RESPONSE WITH ACTEMRA. RENEWAL CRITERIA: DOCUMENTATION OF A POSITIVE RESPONSE.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY RHEUMATOLOGY.

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

KINERET

Drugs

KINERET

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

MAY NOT USE KINERET CONCURRENTLY WITH OTHER BIOLOGIC THERAPIES.

Required Medical Information

INITIAL CRITERIA: (1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) MEDICAL CHART DOCUMENTATION OF BASELINE DISEASE ACTIVITY AND/OR FUNCTIONAL ASSESSMENT AND TREATMENT GOALS (3) FOR RHEUMATOLOGY: MEDICAL CHART DOCUMENTATION OF CONTRAINDICATIONS OR INADEQUATE RESPONSE TO ENBREL AND HUMIRA. RENEWAL CRITERIA: MEDICAL CHART DOCUMENTATION THAT TREATMENT GOALS HAVE BEEN MET FOR THERAPY.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY RHEUMATOLOGY, PEDIATRICIAN (FOR CHILDREN WITH CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES), AND GENETICS SPECIALISTS WITHIN THE SCOPE OF THE APPLICABLE PRESCRIBER SPECIALTY.

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

LATUDA

Drugs

LATUDA

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

FOR NEW START PATIENTS: (1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) DOCUMENTATION OF AN INADEQUATE RESPONSE OR MEDICAL CONTRAINDICATION TO ONE OF THE FOLLOWING ALTERNATIVES: RISPERIDONE, ZIPRASIDONE, OLANZAPINE, QUETIAPINE REGULAR RELEASE, QUETIAPINE EXTENDED RELEASE OR ARIPIPRAZOLE.

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

LIDOCAINE PATCH

Drugs

lidocaine topical adhesive patch,medicated

Covered Uses

ALL MEDICALLY ACCEPTED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

(1) DIAGNOSIS OF A MEDICALLY ACCEPTED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) FOR DIAGNOSIS OF POSTHERPETIC NEURALGIA OR DIABETIC NEUROPATHY, DOCUMENTATION THAT THE PATIENT HAS TRIED AND FAILED GABAPENTIN.

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION.

LOTRONEX

Drugs

alosetron

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D.

Age Restriction

Prescriber Restriction

Coverage Duration

8 WEEKS, THEN BALANCE OF CONTRACT YEAR ONLY IF SIGNIFICANT IMPROVEMENT IN DISABILITY.

Other Criteria

MARQIBO

Drugs

MARQIBO

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

INITIAL CRITERIA FOR NEW START PATIENTS: DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D. RENEWAL CRITERIA: DOCUMENTATION THAT DISEASE PROGRESSION HAS NOT OCCURRED.

Age Restriction

Prescriber Restriction

Coverage Duration

THREE MONTHS, THEN BALANCE OF CONTRACT YEAR IF RENEWAL CRITERIA ARE MET.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

MAVYRET

Drugs **MAVYRET**

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

(1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) DOCUMENTATION OF HEPATITIS C GENOTYPE AND BASELINE VIRAL LOAD, PROVIDER ATTESTATION OF READINESS TO TREAT, PATIENT ATTESTATION OF READINESS FOR TREATMENT, AND SUBMISSION OF VIROLOGIC RESPONSE UPON COMPLETION OF TREATMENT.

Age Restriction

RESERVED FOR PATIENTS AGE 18 AND OLDER.

Prescriber Restriction

RESERVED FOR PRESCRIBING BY GASTROENTEROLOGY, HEPATOLOGY, INFECTIOUS DISEASE SPECIALISTS, OR TRANSPLANT SPECIALIST.

Coverage Duration

8-16 WKS PER DIAGNOSIS, FDA LABELING OR CLINICAL GUIDELINES. 8 WK APPROVALS PER PROVIDER REQUEST.

Other Criteria

DOSE IS LIMITED TO THE FDA-APPROVED REGIMEN OF THREE TABLETS DAILY.

MECASERMIN

Drugs

INCRELEX

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY ENDOCRINOLOGY.

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

MEDICALLY ACCEPTED INDICATIONS

Drugs

armodafinil oral tablet 150 mg, 200 mg, 250 mg, 50 mg, cyclobenzaprine oral tablet 10 mg, 5 mg, modafinil

Covered Uses

ALL MEDICALLY ACCEPTED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

DIAGNOSIS OF AN FDA-APPROVED INDICATION OR CMS-APPROVED COMPENDIA ACCEPTED INDICATION FOR THE REQUESTED MEDICATION.

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

MEDROXYPROGESTERONE 400 MG/ML IM INJECTION

Drugs

DEPO-PROVERA INTRAMUSCULAR SUSPENSION 400 MG/ML

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

(1) DIAGNOSIS OF CANCER FOR A NEW START PATIENT, OR (2) DOCUMENTATION THAT A PATIENT IS CURRENTLY RECEIVING OR HAS PREVIOUSLY RECEIVED AND BENEFITED FROM DEPO-PROVERA 400MG/ML INTRAMUSCULAR INJECTION FOR THE TREATMENT OF CANCER.

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

METABOLIC DISORDER AGENTS

Drugs

ARCALYST, CARBAGLU, KUVAN, RAVICTI, SUCRAID

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

PATIENT MUST NOT HAVE AN FDA-LABELED LIMITATION OF USE OR CONTRAINDICATION TO THERAPY.

Required Medical Information

INITIAL CRITERIA: DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D. RENEWAL CRITERIA: DOCUMENTATION OF POSITIVE RESPONSE.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY PROVIDERS SPECIALIZING IN GENETICS AND METABOLISM

Coverage Duration

THREE MONTHS, THEN BALANCE OF CONTRACT YEAR IF RENEWAL CRITERIA ARE MET.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

METHOXSALLEN

Drugs

methoxsalen

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

FOR NEW START PATIENTS: DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY DERMATOLOGY AND ONCOLOGY WITHIN THE SCOPE OF THE APPLICABLE PRESCRIBER SPECIALTY.

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

MIACALCIN INJECTION

Drugs

MIACALCIN INJECTION

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND DOCUMENTATION OF TRIAL AND FAILURE OR MEDICAL CONTRAINDICATIONS TO BISPHOSPHONATES.

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

THIS DRUG MAY BE COVERED UNDER MEDICARE PART B OR PART D DEPENDING ON THE CIRCUMSTANCES. INFORMATION MAY NEED TO BE SUBMITTED DESCRIBING THE USE OF THE DRUG AND SETTING WHERE THE DRUG IS DISPENSED TO MAKE THE PART B OR PART D COVERAGE DETERMINATION.

MULTAQ

Drugs

MULTAQ

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

(1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) DOCUMENTED FAILURE WITH OR MEDICAL CONTRAINDICATIONS TO FIRST-LINE MEDICATIONS SUCH AS AMIODARONE, FLECAINIDE, PROPAFENONE OR SOTALOL.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY CARDIOLOGY

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

NARCOTIC AGENTS

Drugs

fentanyl citrate buccal lozenge on a handle 200 mcg, 400 mcg, LAZANDA

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

(1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) DOCUMENTATION THAT THE PATIENT HAS DIFFICULTY SWALLOWING OR HAS COMPLIANCE CONCERNS WITH ORAL NARCOTIC TABLETS, CAPSULES, OR LIQUID.

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION.

NATPARA

Drugs **NATPARA**

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

PATIENT MUST NOT HAVE AN FDA-LABELED LIMITATION OF USE OR CONTRAINDICATION TO THERAPY.

Required Medical Information

INITIAL CRITERIA: (1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) HISTORY OF HYPOPARATHYROIDISM FOR AT LEAST 18 MONTHS, AND (3) SERUM THYROID FUNCTION TESTS WITHIN LABORATORY NORMAL LIMITS (FOR PATIENTS NOT ON THYROID REPLACEMENT) OR THYROID REPLACEMENT THERAPY MUST BE STABLE FOR AT LEAST 3 MONTHS (FOR PATIENTS TAKING THYROID REPLACEMENT), AND (4) SERUM MAGNESIUM LEVEL WITHIN LABORATORY NORMAL LIMITS, AND (5) UPON INITIATION OF NATPARA THERAPY, NATPARA TO BE USED AS AN ADJUNCT TO CALCITRIOL AT LEAST 0.25 MCG/DAY. RENEWAL CRITERIA: SERUM CALCIUM CONCENTRATION MUST BE MAINTAINED IN THE LOWER HALF OF LABORATORY NORMAL REFERENCE RANGE.

Age Restriction

LIMITED TO ADULTS AGE 18 YEARS AND OLDER.

Prescriber Restriction

RESERVED FOR PRESCRIBING BY ENDOCRINOLOGY.

Coverage Duration

THREE MONTHS, THEN BALANCE OF CONTRACT YEAR IF RENEWAL CRITERIA ARE MET.

Other Criteria

ALL FDA-LABELED DOSAGE AND ADMINISTRATION GUIDELINES MUST BE MET.

NON-PREFERRED SOMATOSTATIN

Drugs

SIGNIFOR LAR

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

INITIAL: (1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) DOCUMENTATION OF TRIAL AND FAILURE WITH ONE LONG-ACTING SOMATOSTATIN ANALOGUE (SUCH AS SANDOSTATIN LAR). RENEWAL: DOCUMENTATION OF POSITIVE RESPONSE.

Age Restriction

Prescriber Restriction

Coverage Duration

SIX MONTHS, THEN BALANCE OF CONTRACT YEAR IF RENEWAL CRITERIA ARE MET.

Other Criteria

THIS DRUG MAY BE COVERED UNDER MEDICARE PART B OR PART D DEPENDING ON THE CIRCUMSTANCES. INFORMATION MAY NEED TO BE SUBMITTED DESCRIBING THE USE OF THE DRUG AND SETTING WHERE THE DRUG IS DISPENSED TO MAKE THE PART B OR PART D COVERAGE DETERMINATION.

NON-PREFERRED TOBRAMYCIN

Drugs

BETHKIS

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

INITIAL CRITERIA: (1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) DOCUMENTATION OF TRIAL AND FAILURE WITH GENERIC TOBRAMYCIN NEBULIZED SOLUTION, AND (3) CARE MANAGED BY A CYSTIC FIBROSIS SPECIALIST. RENEWAL CRITERIA: DOCUMENTATION OF A POSITIVE RESPONSE AND THE PATIENT HAS BEEN SEEN WITHIN THE LAST 12 MONTHS FOR CYSTIC FIBROSIS.

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

THIS DRUG MAY BE COVERED UNDER MEDICARE PART B OR PART D DEPENDING ON THE CIRCUMSTANCES. INFORMATION MAY NEED TO BE SUBMITTED DESCRIBING THE USE OF THE DRUG AND SETTING WHERE THE DRUG IS DISPENSED TO MAKE THE PART B OR PART D COVERAGE DETERMINATION.

NORTHERA

Drugs

NORTHERA ORAL CAPSULE 100 MG, 200 MG, 300 MG

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

INITIAL CRITERIA: (1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D. RENEWAL CRITERIA: MEDICAL RECORD DOCUMENTATION OF CONTINUED EFFECTIVENESS.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY OR IN CONSULTATION WITH A CARDIOLOGIST OR NEUROLOGIST

Coverage Duration

ONE MONTH, WITH APPROVAL EVERY THREE MONTHS IF RENEWAL CRITERIA ARE MET.

Other Criteria

NUEDEXTA

Drugs

NUEDEXTA

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D.

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION.

OLUMIANT

Drugs

OLUMIANT

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

MAY NOT USE OLUMIANT CONCURRENTLY WITH OTHER BIOLOGIC THERAPIES.

Required Medical Information

INITIAL CRITERIA: (1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) MEDICAL CHART DOCUMENTATION OF BASELINE DISEASE ACTIVITY AND/OR FUNCTIONAL ASSESSMENT AND TREATMENT GOALS, AND (3) FOR RHEUMATOID ARTHRITIS, DOCUMENTATION OF MEDICAL CONTRAINDICATIONS OR INADEQUATE RESPONSE WITH ENBREL AND HUMIRA. RENEWAL CRITERIA: MEDICAL CHART DOCUMENTATION THAT TREATMENT GOALS HAVE BEEN MET FOR THERAPY.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY RHEUMATOLOGY

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

OLYSIO

Drugs **OLYSIO**

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

(1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) DOCUMENTATION OF HEPATITIS C GENOTYPE AND BASELINE VIRAL LOAD, PROVIDER ATTESTATION OF READINESS TO TREAT, PATIENT ATTESTATION OF READINESS FOR TREATMENT, AND SUBMISSION OF VIROLOGIC RESPONSE UPON COMPLETION OF TREATMENT, AND (3) DOCUMENTED CLINICAL INAPPROPRIATENESS OF OR INABILITY TO TOLERATE HARVONI, EPCLUSA, OR MAVYRET. IF GENOTYPE 1A: DOCUMENTATION PATIENT IS NEGATIVE FOR NS3 Q80K POLYMORPHISM.

Age Restriction

RESERVED FOR PATIENTS AGE 18 AND OLDER.

Prescriber Restriction

RESERVED FOR PRESCRIBING BY GASTROENTEROLOGY, HEPATOLOGY, INFECTIOUS DISEASE SPECIALISTS, OR TRANSPLANT SPECIALIST.

Coverage Duration

DURATION PER GENOTYPE AND DIAGNOSIS. 12-24 WEEKS PER FDA APPROVED LABELING OR CLINICAL GUIDELINES.

Other Criteria

DOSE IS LIMITED TO THE FDA-APPROVED DOSE OF 150MG DAILY. MUST BE USED IN A COMBINATION ANTIVIRAL TREATMENT REGIMEN SUPPORTED BY FDA APPROVED LABELING OR RELEVANT CLINICAL GUIDELINES.

ORAL DISSOLVE TABLETS PROTECTED CLASS

Drugs

*aripiprazole oral tablet, disintegrating, clozapine oral tablet, disintegrating, olanzapine oral tablet, disintegrating, risperidone oral tablet, disintegrating, **SPRITAM***

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

FOR NEW START PATIENTS: (1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) DOCUMENTATION OF FAILURE WITH OR CONTRAINDICATION TO ONE REGULAR TABLET DOSAGE FORM OF THE REQUESTED MEDICATION.

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

ORAL LIQUID PROTECTED CLASS

Drugs

VERSACLOZ

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

FOR NEW START PATIENTS: (1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) DOCUMENTATION THAT THE PATIENT HAS DIFFICULTY SWALLOWING OR HAS COMPLIANCE CONCERNS WITH REGULAR TABLET OR CAPSULE DOSAGE FORMS.

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

ORAL ONCOLOGY AGENTS

Drugs

ALECENSA, ALUNBRIG, BOSULIF, BRAFTOVI, CABOMETYX, CALQUENCE, COMETRIQ, COPIKTRA, COTELLIC, DAURISMO, ERIVEDGE, ERLEADA, FARYDAK, GILOTRIF, IBRANCE, ICLUSIG, IDHIFA, IMBRUVICA, INLYTA, IRESSA, JAKAFI, KISQALI, KISQALI FEMARA CO-PACK, LENVIMA, LONSURF, LORBRENA, LYNPARZA, MEKINIST, MEKTOVI, NERLYNX, NINLARO, ODOMZO, POMALYST, RUBRACA, RYDAPT, STIVARGA, TAFINLAR, TAGRISSO, TALZENNA, TIBSOVO, VENCLEXTA, VENCLEXTA STARTING PACK, VERZENIO, VITRAKVI, VIZIMPRO, XALKORI, XOSPATA, YONSA, ZEJULA, ZELBORAF, ZOLINZA, ZYDELIG, ZYKADIA

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

PATIENT MUST NOT HAVE AN FDA-LABELED LIMITATION OF USE OR CONTRAINDICATION TO THERAPY.

Required Medical Information

INITIAL CRITERIA FOR NEW START PATIENTS: DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D. RENEWAL CRITERIA: DOCUMENTATION THAT DISEASE PROGRESSION HAS NOT OCCURRED.

Age Restriction

Prescriber Restriction

Coverage Duration

SIX MONTHS, THEN BALANCE OF CONTRACT YEAR IF RENEWAL CRITERIA ARE MET.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

ORENCIA

Drugs

ORENCIA, ORENCIA (WITH MALTOSE), ORENCIA CLICKJECT

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

MAY NOT USE ORENCIA CONCURRENTLY WITH OTHER BIOLOGIC THERAPIES.

Required Medical Information

INITIAL CRITERIA: (1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) MEDICAL CHART DOCUMENTATION OF BASELINE DISEASE ACTIVITY AND/OR FUNCTIONAL ASSESSMENT AND TREATMENT GOALS, AND (3) DOCUMENTATION OF MEDICAL CONTRAINDICATIONS OR INADEQUATE RESPONSE WITH ENBREL AND HUMIRA. RENEWAL CRITERIA: MEDICAL CHART DOCUMENTATION THAT TREATMENT GOALS HAVE BEEN MET FOR THERAPY.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY RHEUMATOLOGY

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

ORENITRAM

Drugs

ORENITRAM

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

PATIENT MUST NOT HAVE AN FDA-LABELED LIMITATION OF USE OR CONTRAINDICATION TO THERAPY.

Required Medical Information

(1) (A) DIAGNOSIS OF VASOREACTIVE PULMONARY ARTERIAL HYPERTENSION (PAH) AS CONFIRMED BY PRETREATMENT RIGHT HEART CATHETERIZATION AND TRIAL AND FAILURE OF CALCIUM CHANNEL BLOCKER THERAPY, OR (B) DIAGNOSIS OF NON-VASOREACTIVE PAH AS CONFIRMED BY PRETREATMENT RIGHT HEART CATHETERIZATION, AND (2) A PREVIOUS TRIAL OF ONE PREFERRED AGENT SUCH AS UPTRAVI, AND (3) DEMONSTRATED MEDICAL NECESSITY.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY PULMONOLOGY OR CARDIOLOGY.

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

ORILISSA

Drugs

ORILISSA ORAL TABLET 150 MG, 200 MG

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

PATIENT MUST NOT HAVE AN FDA-LABELED LIMITATION OF USE OR CONTRAINDICATION TO THERAPY.

Required Medical Information

(1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) PATIENT HAS A DOCUMENTED INADEQUATE RESPONSE OR MEDICAL CONTRAINDICATION TO (A) PRESCRIPTION STRENGTH NSAID, AND (B) CONTINUOUS ORAL CONTRACEPTIVE THERAPY OR PROGESTERONE THERAPY.

Age Restriction

RESERVED FOR PATIENTS AGE 18 AND OLDER.

Prescriber Restriction

RESERVED FOR PRESCRIBING BY OR IN CONSULTATION WITH OBSTETRICS/GYNECOLOGY.

Coverage Duration

SIX MONTHS, THEN BALANCE OF CONTRACT YEAR IF RENEWAL CRITERIA ARE MET.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

OTEZLA

Drugs

OTEZLA, OTEZLA STARTER

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

PLAQUE PSORIASIS INITIAL CRITERIA: (1) DIAGNOSIS OF MODERATE TO SEVERE PLAQUE PSORIASIS (AT LEAST 5% BODY SURFACE AREA, OR PRESENTATION IN PALMAR, PLANTAR, FACIAL, SCALP, AND/OR GENITAL REGIONS, OR PUSTULAR PSORIASIS), AND (2) MEDICAL CHART DOCUMENTATION OF BASELINE DISEASE ACTIVITY AND TREATMENT GOALS. PSORIATIC ARTHRITIS INITIAL CRITERIA: (1) DIAGNOSIS OF PSORIATIC ARTHRITIS, AND (2) MEDICAL CHART DOCUMENTATION OF BASELINE DISEASE ACTIVITY AND/OR FUNCTIONAL ASSESSMENT AND TREATMENT GOALS. RENEWAL CRITERIA: MEDICAL CHART DOCUMENTATION THAT TREATMENT GOALS HAVE BEEN MET FOR THERAPY, OR THAT SIGNIFICANT PROGRESS TOWARD ACHIEVEMENT OF TREATMENT GOALS HAS OCCURRED.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY RHEUMATOLOGY OR DERMATOLOGY.

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

PANTOPRAZOLE IV

Drugs

pantoprazole intravenous

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

(1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) DOCUMENTATION OF: (A) FAILURE WITH ORAL FORMULARY PROTON PUMP INHIBITORS OMEPRAZOLE AND LANSOPRAZOLE, OR (B) MEDICAL CONTRAINDICATIONS TO ORAL PROTON PUMP INHIBITORS.

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

PARICALCITOL

Drugs

paricalcitol oral

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

(1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) DOCUMENTATION OF FAILURE WITH CALCITRIOL.

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

THIS DRUG MAY BE COVERED UNDER MEDICARE PART B OR PART D DEPENDING ON THE CIRCUMSTANCES. INFORMATION MAY NEED TO BE SUBMITTED DESCRIBING THE USE OF THE DRUG AND SETTING WHERE THE DRUG IS DISPENSED TO MAKE THE PART B OR PART D COVERAGE DETERMINATION.

PART B DRUGS

Drugs

acetylcysteine, acyclovir sodium intravenous recon soln 500 mg, acyclovir sodium intravenous solution, albuterol sulfate inhalation solution for nebulization 0.63 mg/3 ml, 1.25 mg/3 ml, 2.5 mg /3 ml (0.083 %), 5 mg/ml, AMINOSYN 8.5 %-ELECTROLYTES, AMINOSYN II 10 %, AMINOSYN II 15 %, AMINOSYN II 7 %, AMINOSYN II 8.5 %, AMINOSYN II 8.5 %-ELECTROLYTES, AMINOSYN M 3.5 %, AMINOSYN-HBC 7%, AMINOSYN-PF 10 %, AMINOSYN-PF 7 % (SULFITE-FREE), aprepitant, AZASAN, azathioprine, azathioprine sodium, BCG VACCINE, LIVE (PF), budesonide inhalation, cromolyn inhalation, cyclophosphamide oral capsule, cyclosporine intravenous, cyclosporine modified, cyclosporine oral capsule, deltasone oral tablet 20 mg, dexamethasone oral elixir, dexamethasone oral tablet, dronabinol oral capsule 10 mg, 2.5 mg, 5 mg, EMEND ORAL SUSPENSION FOR RECONSTITUTION, ENGERIX-B (PF), ENGERIX-B PEDIATRIC (PF) INTRAMUSCULAR SYRINGE, ganciclovir sodium, gengraf, granisetron hcl oral, heparin (porcine) in 5 % dex intravenous parenteral solution 20,000 unit/500 ml (40 unit/ml), IMOVAX RABIES VACCINE (PF), INTRALIPID INTRAVENOUS EMULSION 20 %, 30 %, ipratropium bromide inhalation, ipratropium-albuterol, methotrexate sodium, methotrexate sodium (pf) injection solution, methylprednisolone oral tablet, MILLIPRED ORAL TABLET, mycophenolate mofetil, mycophenolate mofetil hcl, NEBUPENT, NULOJIX, ondansetron, ondansetron hcl oral, prednisolone oral solution 15 mg/5 ml, prednisolone sodium phosphate oral solution 10 mg/5 ml, 20 mg/5 ml (4 mg/ml), 25 mg/5 ml (5 mg/ml), 5 mg base/5 ml (6.7 mg/5 ml), PREDNISON INTENSOL, prednisone oral solution, prednisone oral tablet, PROGRAF INTRAVENOUS, RABAVERT (PF), RAPAMUNE ORAL SOLUTION, RECOMBIVAX HB (PF), SIMULECT, sirolimus, tacrolimus oral, TICE BCG, trimethobenzamide oral

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

THIS DRUG MAY BE COVERED UNDER MEDICARE PART B OR PART D DEPENDING ON THE CIRCUMSTANCES. INFORMATION MAY NEED TO BE SUBMITTED DESCRIBING THE USE OF THE DRUG AND SETTING WHERE THE DRUG IS DISPENSED TO MAKE THE PART B OR PART D COVERAGE DETERMINATION.

PEGASYS

Drugs

PEGASYS, PEGASYS PROCLICK

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

(1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) FOR TREATMENT OF HEPATITIS C, DOCUMENTATION OF HCV GENOTYPE, VIRAL LOAD AND LIVER FUNCTION TESTS, AND DOCUMENTATION OF INTOLERANCE TO OR ADVERSE EFFECTS FROM PRIOR USE OF PEGINTRON.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY GASTROENTEROLOGY, OR HEPATOLOGY, OR INFECTIOUS DISEASE SPECIALISTS.

Coverage Duration

12-48 WEEKS PER FDA APPROVED LABELING OR CLINICAL GUIDELINES FOR PATIENT DIAGNOSIS AND GENOTYPE.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES. CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD-IDS A GUIDANCE.

PEGINTRON

Drugs

PEGINTRON SUBCUTANEOUS KIT 50 MCG/0.5 ML

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

(1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) FOR TREATMENT OF HEPATITIS C, DOCUMENTATION OF HCV GENOTYPE, VIRAL LOAD AND LIVER FUNCTION TESTS.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY GASTROENTEROLOGY, OR HEPATOLOGY, OR INFECTIOUS DISEASE SPECIALISTS.

Coverage Duration

DURATION PER DIAGNOSIS. 12-48 WEEKS PER FDA APPROVED LABELING OR CLINICAL GUIDELINES.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES. CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD-IDSA GUIDANCE.

PENICILLAMINE

Drugs

d-penaminate, **DEPEN TITRATABS**

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

(1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) FOR CYSTINURIA: DOCUMENTATION OF MEDICAL CONTRAINDICATIONS OR INADEQUATE RESPONSE TO THIOLA. RENEWAL CRITERIA: DOCUMENTATION OF POSITIVE RESPONSE TO THERAPY.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY PROVIDERS SPECIALIZING IN GENETICS AND METABOLISM, GASTROENTEROLOGY, HEPATOLOGY, AND NEPHROLOGY WITHIN THE SCOPE OF THE APPLICABLE PRESCRIBER SPECIALTY.

Coverage Duration

SIX MONTHS, THEN BALANCE OF CONTRACT YEAR IF RENEWAL CRITERIA ARE MET.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

PHENOXYBENZAMINE

Drugs

phenoxybenzamine

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

(1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) DOCUMENTATION OF AN INADEQUATE RESPONSE OR MEDICAL CONTRAINDICATION TO ONE GENERIC ALPHA-BLOCKER, SUCH AS TERAZOSIN OR DOXAZOSIN.

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

PRADAXA

Drugs

PRADAXA

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

(1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) DOCUMENTATION OF INADEQUATE RESPONSE OR MEDICAL CONTRAINDICATION TO XARELTO AND ELIQUIS.

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

PROCARBAZINE

Drugs

MATULANE

Covered Uses

ALL MEDICALLY ACCEPTED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

(1) USE IN COMBINATION WITH OTHER ANTICANCER DRUGS FOR THE TREATMENT OF STAGE III AND IV HODGKIN'S DISEASE, OR (2) DIAGNOSIS OF A MEDICALLY-ACCEPTED INDICATION. RENEWAL: DOCUMENTATION OF POSITIVE RESPONSE.

Age Restriction

Prescriber Restriction

Coverage Duration

SIX MONTHS, THEN BALANCE OF CONTRACT YEAR IF RENEWAL CRITERIA ARE MET.

Other Criteria

DOSE UP TO THE RECOMMENDED MAX OF 6 MG/KG/DAY FOR ADULTS OR 100 MG PER SQUARE METER PER DAY FOR PEDIATRICS.

PROMACTA

Drugs

PROMACTA

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY HEMATOLOGY AND HEPATOLOGY WITHIN THE SCOPE OF THE APPLICABLE PRESCRIBER SPECIALTY.

Coverage Duration

SIX MONTHS, THEN BALANCE OF CONTRACT YEAR IF POSITIVE RESPONSE.

Other Criteria

PULMONARY ARTERIAL HYPERTENSION - NON-ORAL

Drugs

epoprostenol (glycine), **REMODULIN**, *sildenafil (antihypertensive)*, **TYVASO**, **VELETRI**, **VENTAVIS**

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

PATIENT MUST NOT HAVE AN FDA-LABELED LIMITATION OF USE OR CONTRAINDICATION TO THERAPY.

Required Medical Information

(1) DIAGNOSIS OF VASOREACTIVE PULMONARY ARTERIAL HYPERTENSION (PAH) AS CONFIRMED BY PRETREATMENT RIGHT HEART CATHETERIZATION AND TRIAL AND FAILURE OF CALCIUM CHANNEL BLOCKER THERAPY, OR (2) DIAGNOSIS OF NON-VASOREACTIVE PAH AS CONFIRMED BY PRETREATMENT RIGHT HEART CATHETERIZATION.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY PULMONOLOGY OR CARDIOLOGY.

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

THIS DRUG MAY BE COVERED UNDER MEDICARE PART B OR PART D DEPENDING ON THE CIRCUMSTANCES. INFORMATION MAY NEED TO BE SUBMITTED DESCRIBING THE USE OF THE DRUG AND SETTING WHERE THE DRUG IS DISPENSED TO MAKE THE PART B OR PART D COVERAGE DETERMINATION.

PULMONARY ARTERIAL HYPERTENSION - ORAL PREFERRED

Drugs

ADEMPAS, LETAIRIS, OPSUMIT, TRACLEER, UPTRAVI

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

PATIENT MUST NOT HAVE AN FDA-LABELED LIMITATION OF USE OR CONTRAINDICATION TO THERAPY.

Required Medical Information

(1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) FOR VASOREACTIVE PULMONARY ARTERIAL HYPERTENSION (PAH) ONLY, CONFIRMED BY PRETREATMENT RIGHT HEART CATHETERIZATION AND TRIAL AND FAILURE OF CALCIUM CHANNEL BLOCKER THERAPY, AND (3) FOR NON-VASOREACTIVE PAH ONLY, CONFIRMED BY PRETREATMENT RIGHT HEART CATHETERIZATION.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY PULMONOLOGY OR CARDIOLOGY.

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

Drugs

RASUVO (PF) SUBCUTANEOUS AUTO-INJECTOR 10 MG/0.2 ML, 12.5 MG/0.25 ML, 15 MG/0.3 ML, 17.5 MG/0.35 ML, 20 MG/0.4 ML, 22.5 MG/0.45 ML, 25 MG/0.5 ML, 30 MG/0.6 ML, 7.5 MG/0.15 ML

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

RESERVED FOR PATIENTS WHO HAVE: (1) LACK OF RESPONSE TO GENERIC METHOTREXATE INJECTION, OR (2) INTOLERANCE OR SIGNIFICANT ADVERSE EFFECTS FROM GENERIC METHOTREXATE INJECTION, OR (3) DEXTERITY CONCERNS, OR (4) VISUAL ACUITY CONCERNS, OR (5) IMPAIRED COGNITION PREVENTING SAFE USE OF GENERIC METHOTREXATE INJECTION, OR (6) MEDICAL CHART DOCUMENTATION OF NEEDLE PHOBIA PREVENTING USE OF GENERIC METHOTREXATE INJECTION.

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

REMICADE

Drugs

REMICADE

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

MAY NOT USE REMICADE CONCURRENTLY WITH OTHER BIOLOGIC THERAPIES.

Required Medical Information

INITIAL CRITERIA: (1) DIAGNOSIS OF ANKYLOSING SPONDYLITIS, RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, PLAQUE PSORIASIS, CROHN'S DISEASE OR ULCERATIVE COLITIS, AND (2) MEDICAL CHART DOCUMENTATION OF BASELINE DISEASE ACTIVITY AND/OR FUNCTIONAL ASSESSMENT AND TREATMENT GOALS, AND (3) CONCURRENT USE WITH METHOTREXATE (FOR RHEUMATOLOGY INDICATIONS ONLY), AND (4) MEDICAL CHART DOCUMENTATION OF CONTRAINDICATIONS OR INADEQUATE RESPONSE TO: (A) ENBREL AND HUMIRA (FOR RHEUMATOLOGY AND DERMATOLOGICAL INDICATIONS), OR (B) HUMIRA (FOR GASTROENTEROLOGY INDICATIONS OTHER THAN FISTULIZING CROHNS DISEASE). RENEWAL CRITERIA: MEDICAL CHART DOCUMENTATION THAT TREATMENT GOALS HAVE BEEN MET FOR THERAPY.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY DERMATOLOGY, GASTROENTEROLOGY AND RHEUMATOLOGY WITHIN THE SCOPE OF THE APPLICABLE PRESCRIBER SPECIALTY.

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

REPATHA

Drugs

REPATHA PUSHTRONEX, REPATHA SURECLICK, REPATHA SYRINGE

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

INITIAL CRITERIA: (1) DIAGNOSIS OF (A) HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA CONFIRMED WITH CLINICAL CRITERIA SUCH AS WHO CLINICAL CRITERIA SCORE GREATER THAN OR EQUAL TO 6, OR (B) ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AS DEFINED BY THE 2013 ACC/AHA GUIDELINE ON THE TREATMENT OF BLOOD CHOLESTEROL TO REDUCE ARTEROSCLEROTIC CARDIOVASCULAR RISK IN ADULTS, OR (C) HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, AND (2) DOCUMENTATION OF (A) INABILITY TO ACHIEVE AND MAINTAIN LDL LEVEL LESS THAN OR EQUAL TO 100 MG/DL WITH STANDARD THERAPY (DEFINED AS A HIGH INTENSITY STATIN SUCH AS ATORVASTATIN 40-80MG DAILY), OR (B) INTOLERANCE (DEFINED AS INTOLERABLE MYALGIA OR MYOPATHY, OR ALT GREATER THAN OR EQUAL TO 3 TIMES ULN) TO STATIN THERAPY PROVEN WITH TWO TRIALS, OR (C) CONTRAINDICATIONS (DEFINED AS MYOSITIS WITH CREATINE KINASE LEVEL GREATER THAN OR EQUAL TO 10 TIMES ULN OR RHABDOMYOLYSIS) TO STANDARD THERAPY, AND (3) DOCUMENTATION OF CURRENT CHOLESTEROL LAB VALUES AND CHOLESTEROL TREATMENT HISTORY. RENEWAL CRITERIA: MEDICAL CHART DOCUMENTATION THAT TREATMENT GOALS HAVE BEEN MET FOR THERAPY, OR THAT SIGNIFICANT PROGRESS TOWARD ACHIEVEMENT OF TREATMENT GOALS HAS OCCURRED.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY OR IN CONSULTATION WITH CARDIOLOGY, ENDOCRINOLOGY, OR LIPIDOLOGY SPECIALISTS

Coverage Duration

THREE MONTHS, THEN BALANCE OF CONTRACT YEAR IF RENEWAL CRITERIA ARE MET.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

RITUXAN

Drugs

RITUXAN

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D, DIAGNOSIS AUTOIMMUNE HEMOLYTIC ANEMIA, AND DIAGNOSIS OF IDIOPATHIC THROMBOCYTOPENIC PURPURA.

Exclusion Criteria

Required Medical Information

RHEUMATOLOGY: (1) DIAGNOSIS OF AN FDA-APPROVED RHEUMATOLOGY DISORDER, AND (2) DOCUMENTATION OF MEDICAL CONTRAINDICATIONS OR FAILURE WITH ENBREL AND HUMIRA. HEMATOLOGY: (1) DIAGNOSIS OF IDIOPATHIC THROMBOCYTOPENIC PURPURA OR AUTOIMMUNE HEMOLYTIC ANEMIA AND (2) PATIENTS WITH INADEQUATE RESPONSE OR MEDICAL CONTRAINDICATIONS TO CORTICOSTEROIDS .

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY ONCOLOGY , HEMATOLOGY AND RHEUMATOLOGY WITHIN THE SCOPE OF THE APPLICABLE PRESCRIBER SPECIALTY.

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

THIS DRUG MAY BE COVERED UNDER MEDICARE PART B OR PART D DEPENDING ON THE CIRCUMSTANCES. INFORMATION MAY NEED TO BE SUBMITTED DESCRIBING THE USE OF THE DRUG AND SETTING WHERE THE DRUG IS DISPENSED TO MAKE THE PART B OR PART D COVERAGE DETERMINATION.

SABRIL

Drugs

SABRIL ORAL TABLET, *vigabatrin*, *vigadrone*

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

FOR NEW START PATIENTS: (1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) DOCUMENTED FAILURE ON TWO OTHER FORMULARY SEIZURE MEDICATIONS SUCH AS CARBAMAZEPINE, DIVALPROEX, LEVETIRACETAM, GABAPENTIN, TOPIRAMATE, AND OTHERS.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY NEUROLOGIST

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

SEROSTIM

Drugs

SEROSTIM SUBCUTANEOUS RECON SOLN 4 MG, 5 MG, 6 MG

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

DOCUMENTATION THAT OTHER THERAPIES HAVE PROVEN INEFFECTIVE FOR HIV-INFECTED PATIENTS DIAGNOSED WITH SIGNIFICANT WASTING.

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

SIGNIFOR

Drugs

SIGNIFOR

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

INITIAL: (1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D. RENEWAL: DOCUMENTATION OF BENEFICIAL RESPONSE.

Age Restriction

Prescriber Restriction

Coverage Duration

THREE MONTHS, THEN BALANCE OF CONTRACT YEAR IF RENEWAL CRITERIA ARE MET.

Other Criteria

SILDENAFIL

Drugs

sildenafil (antihypertensive)

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

PATIENT MUST NOT HAVE AN FDA-LABELED LIMITATION OF USE OR CONTRAINDICATION TO THERAPY.

Required Medical Information

(1) DIAGNOSIS OF VASOREACTIVE PULMONARY ARTERIAL HYPERTENSION (PAH) AS CONFIRMED BY PRETREATMENT RIGHT HEART CATHETERIZATION AND TRIAL AND FAILURE OF CALCIUM CHANNEL BLOCKER THERAPY, OR (2) DIAGNOSIS OF NON-VASOREACTIVE PAH AS CONFIRMED BY PRETREATMENT RIGHT HEART CATHETERIZATION.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY PULMONOLOGY OR CARDIOLOGY.

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION.

SILIQ

Drugs SILIQ

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

MAY NOT USE SILIQ CONCURRENTLY WITH OTHER BIOLOGIC THERAPIES.

Required Medical Information

PLAQUE PSORIASIS INITIAL CRITERIA: (1) DIAGNOSIS OF MODERATE TO SEVERE PLAQUE PSORIASIS (AT LEAST 5% BODY SURFACE AREA, OR PRESENTATION IN PALMAR, PLANTAR, FACIAL, SCALP AND/OR GENITAL REGIONS, OR PUSTULAR PSORIASIS), AND (2) MEDICAL CHART DOCUMENTATION OF BASELINE DISEASE ACTIVITY AND TREATMENT GOALS, AND (3) MEDICAL CHART DOCUMENTATION OF CONTRAINDICATIONS OR INADEQUATE RESPONSE WITH COSENTYX AND TALTZ. RENEWAL CRITERIA: MEDICAL CHART DOCUMENTATION THAT TREATMENT GOALS HAVE BEEN MET FOR THERAPY.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY DERMATOLOGY

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

SIMPONI

Drugs SIMPONI

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

MAY NOT USE SIMPONI CONCURRENTLY WITH OTHER BIOLOGIC THERAPIES.

Required Medical Information

INITIAL CRITERIA: (1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) MEDICAL CHART DOCUMENTATION OF BASELINE DISEASE ACTIVITY AND/OR FUNCTIONAL ASSESSMENT AND TREATMENT GOALS, AND (3) FOR RHEUMATOLOGY: MEDICAL CHART DOCUMENTATION OF CONTRAINDICATIONS OR INADEQUATE RESPONSE WITH ENBREL AND HUMIRA, OR FOR GASTROENTEROLOGY: DOCUMENTATION OF MEDICAL CONTRAINDICATIONS OR INADEQUATE RESPONSE TO HUMIRA. RENEWAL CRITERIA: MEDICAL CHART DOCUMENTATION THAT TREATMENT GOALS HAVE BEEN MET FOR THERAPY.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY RHEUMATOLOGY AND GASTROENTEROLOGY WITHIN THE SCOPE OF THE APPLICABLE PRESCRIBER SPECIALTY.

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

SOMATROPIN

Drugs

NORDITROPIN FLEXPRO

Covered Uses

ALL MEDICALLY ACCEPTED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

CRITERIA FOR CHILDREN: EITHER 1 OR 2 OR 3: (1) SHORT STATURE INITIAL: A) CURRENT HEIGHT IS 2.25 OR MORE STANDARD DEVIATIONS BELOW NORMAL, OR B) TARGET ADULT HEIGHT OF 2 OR MORE STANDARD DEVIATIONS BELOW MIDPARENTAL HEIGHT, OR C) HEIGHT VELOCITY OF MINUS 2 OR MORE STANDARD DEVIATIONS FOR AGE AND TANNER STAGE, AND D) GROWTH HORMONE (GH) PROVOCATIVE TESTING (GH PEAK LESS THAN 10 MG/ML), OR E) SERUM IGF LEVELS (IGF-1 OR IGFBP-3) LESS THAN 1 STANDARD DEVIATION BELOW NORMAL, OR F) IGF GENERATION TEST (STIMULATE LEVEL 3 TIMES BASELINE OR GREATER THAN 250MG/ML). (1) SHORT STATURE RENEWAL: A) DOCUMENTATION OF POSITIVE RESPONSE, AND B) GROWTH VELOCITY IS GREATER THAN OR EQUAL TO 2 CM/YEAR, AND C) PATIENT HAS NOT ACHIEVED MATURE BONE AGE (17 OR GREATER FOR BOYS OR 15 OR GREATER FOR GIRLS), (2) PANHYPOPITUITARISM, (3) DIAGNOSIS OF PRADER-WILLI, TURNER SYNDROME, OR NOONAN SYNDROME AND EPIPHYSES ARE NOT CLOSED. CRITERIA FOR ADULTS: PATIENT HAS GROWTH HORMONE DEFICIENCY (GHD) WITH 1 OR 2 AND 3 AND 4 AND 5 LISTED BELOW: (1) HISTORY OF HYPOTHALAMIC OR PITUITARY DISEASE OR HISTORY OF CRANIAL IRRADIATION, OR (2) LOW IGF-1 LEVELS BASED ON AGE ADJUSTED VALUES AND SERUM GROWTH HORMONE CONCENTRATION OF LESS THAN 5NG/ML (PEAK LEVELS) FOLLOWING STIMULATION TESTING. ITT (INSULIN TOLERANCE TEST) IS THE DIAGNOSTIC TEST OF CHOICE UNLESS CONTRAINDICATED, AND (3) COMPLETE PITUITARY HORMONE FUNCTION HAS BEEN TESTED AND REPLACED WHEN APPROPRIATE, AND (4) THREE OF THE FOLLOWING: A) ALTERED BODY COMPOSITION WITH INCREASED BODY FAT MASS AND DECREASED LEAN BODY MASS, OR B) DECREASED MUSCLE STRENGTH AND EXERCISE CAPACITY, OR C) REDUCED BONE DENSITY OR PRESENCE OF A FRAGILITY FRACTURE, OR D) POOR SLEEP, OR E) IMPAIRED SENSE OF WELL BEING, AND (5) SECONDARY MEDICAL ILLNESSES THAT AFFECT GH HAVE BEEN RULED OUT.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY ENDOCRINOLOGY

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

STELARA

Drugs **STELARA**

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

MAY NOT USE STELARA CONCURRENTLY WITH OTHER BIOLOGIC THERAPIES.

Required Medical Information

PLAQUE PSORIASIS INITIAL CRITERIA: (1) (A) DIAGNOSIS OF MODERATE TO SEVERE PLAQUE PSORIASIS (AT LEAST 5% BODY SURFACE AREA, OR PRESENTATION IN PALMAR, PLANTAR, FACIAL, SCALP, AND/OR GENITAL REGIONS, OR PUSTULAR PSORIASIS), OR (B) PSORIATIC ARTHRITIS, AND (2) MEDICAL CHART DOCUMENTATION OF BASELINE DISEASE ACTIVITY AND TREATMENT GOALS, AND (3) MEDICAL CHART DOCUMENTATION OF CONTRAINDICATIONS OR INADEQUATE RESPONSE WITH COSENTYX. MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE INITIAL: (1) DOCUMENTATED CONTRAINDICATION, INTOLERANCE TO, OR FAILURE ON 1 OF THE FOLLOWING: PREDNISONE OR A CORTICOSTEROID EQUIVALENT FOR 2 WEEKS, OR AN IMMUNOMODULATORY MED FOR 3 OR MORE MOS, AND (2) MEDICAL CHART DOCUMENTATION OF CONTRAINDICATIONS OR INADEQUATE RESPONSE TO HUMIRA. RENEWAL CRITERIA: MEDICAL CHART DOCUMENTATION THAT TREATMENT GOALS HAVE BEEN MET FOR THERAPY, OR THAT SIGNIFICANT PROGRESS TOWARD ACHIEVEMENT OF TREATMENT GOALS HAS OCCURRED.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY DERMATOLOGY, RHEUMATOLOGY, AND GASTROENTEROLOGY WITHIN THE SCOPE OF THE APPLICABLE PRESCRIBER SPECIALTY.

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

SUBLINGUAL IMMUNOTHERAPY

Drugs

GRASTEK, RAGWITEK

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

(1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) DOCUMENTATION OF TRIAL AND FAILURE OF SUBCUTANEOUS IMMUNOTHERAPY.

Age Restriction

LIMITED TO THOSE AGES SPECIFIED WITHIN THE FDA-APPROVED LABEL

Prescriber Restriction

RESERVED FOR PRESCRIBING BY OR IN CONSULTATION WITH AN ALLERGIST OR IMMUNOLOGIST

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

SYNRIBO

Drugs

SYNRIBO

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

INITIAL CRITERIA FOR NEW START PATIENTS: DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D. RENEWAL CRITERIA: DOCUMENTATION THAT DISEASE PROGRESSION HAS NOT OCCURRED

Age Restriction

Prescriber Restriction

Coverage Duration

THREE MONTHS, THEN BALANCE OF CONTRACT YEAR IF RENEWAL CRITERIA ARE MET.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

TADALAFIL

Drugs

tadalafil (antihypertensive)

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

(1)(A) DIAGNOSIS OF VASOREACTIVE PULMONARY ARTERIAL HYPERTENSION (PAH) AS CONFIRMED BY PRETREATMENT RIGHT HEART CATHETERIZATION AND TRIAL AND FAILURE OF CALCIUM CHANNEL BLOCKER THERAPY, OR (B) DIAGNOSIS OF NON-VASOREACTIVE PAH AS CONFIRMED BY PRETREATMENT RIGHT HEART CATHETERIZATION, AND (2) TRIAL AND FAILURE OF SILDENAFIL ORAL.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY PULMONOLOGY OR CARDIOLOGY.

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

Drugs

TALTZ AUTOINJECTOR, TALTZ SYRINGE

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

MAY NOT USE TALTZ CONCURRENTLY WITH OTHER BIOLOGIC THERAPIES.

Required Medical Information

INITIAL CRITERIA: (1) DIAGNOSIS OF: (A) MODERATE TO SEVERE PLAQUE PSORIASIS (AT LEAST 5% BODY SURFACE AREA, OR PRESENTATION IN PALMAR, PLANTAR, FACIAL, SCALP AND/OR GENITAL REGIONS, OR PUSTULAR PSORIASIS), OR (B) PSORIATIC ARTHRITIS, AND (2) MEDICAL CHART DOCUMENTATION OF BASELINE DISEASE ACTIVITY AND TREATMENT GOALS, AND (3) MEDICAL CHART DOCUMENTATION OF CONTRAINDICATIONS OR INADEQUATE RESPONSE WITH COSENTYX. RENEWAL CRITERIA: MEDICAL CHART DOCUMENTATION THAT TREATMENT GOALS HAVE BEEN MET FOR THERAPY.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY DERMATOLOGY AND RHEUMATOLOGY WITHIN THE SCOPE OF THE APPLICABLE PRESCRIBER SPECIALTY

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

THALASSEMIA AGENTS

Drugs

EXJADE, FERRIPROX, JADENU, JADENU SPRINKLE

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

PATIENT MUST NOT HAVE AN FDA-LABELED LIMITATION OF USE OR CONTRAINDICATION TO THERAPY.

Required Medical Information

DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY HEMATOLOGY AND ONCOLOGY.

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

THIOLA

Drugs

THIOLA

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY NEUROLOGY OR NEPHROLOGY.

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

TREMFYA

Drugs

TREMFYA

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

MAY NOT USE TREMFYA CONCURRENTLY WITH OTHER BIOLOGIC THERAPIES.

Required Medical Information

PLAQUE PSORIASIS INITIAL CRITERIA: (1) DIAGNOSIS OF MODERATE TO SEVERE PLAQUE PSORIASIS (AT LEAST 5% BODY SURFACE AREA, OR PRESENTATION IN PALMAR, PLANTAR, FACIAL, SCALP AND/OR GENITAL REGIONS, OR PUSTULAR PSORIASIS), AND (2) MEDICAL CHART DOCUMENTATION OF BASELINE DISEASE ACTIVITY AND TREATMENT GOALS, AND (3) MEDICAL CHART DOCUMENTATION OF CONTRAINDICATIONS OR INADEQUATE RESPONSE WITH COSENTYX. RENEWAL CRITERIA: MEDICAL CHART DOCUMENTATION THAT TREATMENT GOALS HAVE BEEN MET FOR THERAPY.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY DERMATOLOGY

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

TRICYCLIC ANTIDEPRESSANTS IN ELDERLY

Drugs

amitriptyline, doxepin oral, imipramine hcl, trimipramine

Covered Uses

ALL MEDICALLY ACCEPTED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

FOR NEW START PATIENTS: DIAGNOSIS OF A MEDICALLY ACCEPTED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND DOCUMENTATION THAT THE PATIENT IS MONITORED FOR ADVERSE DRUG EVENTS.

Age Restriction

RESTRICTIONS APPLY TO PATIENTS GREATER THAN 64 YEARS OF AGE.

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

TRIENTINE

Drugs

trientine

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

INITIAL CRITERIA: (1) DIAGNOSIS OF WILSON'S DISEASE AND (2) DEMONSTRATED INTOLERANCE TO PENICILLAMINE. RENEWAL CRITERIA: DOCUMENTATION OF POSITIVE RESPONSE.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY PROVIDERS SPECIALIZING IN GENETICS AND METABOLISM, GASTROENTEROLOGY, AND HEPATOLOGY WITHIN THE SCOPE OF THE APPLICABLE PRESCRIBER SPECIALTY.

Coverage Duration

SIX MONTHS, THEN BALANCE OF CONTRACT YEAR IF POSITIVE RESPONSE.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

TYMLOS

Drugs

TYMLOS

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

(1) DIAGNOSIS OF POSTMENOPAUSAL OSTEOPOROSIS AT HIGH RISK FOR FRACTURE DEFINED AS A HISTORY OF OSTEOPOROTIC FRACTURE OR MULTIPLE RISK FACTORS FOR FRACTURE, OR (2) POSTMENOPAUSAL OSTEOPOROSIS AND (A) INTOLERANCE TO, FAILURE WITH, OR CONTRAINDICATION TO BISPHOSPHONATE THERAPY.

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

TYSABRI

Drugs

TYSABRI

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

PATIENT MUST NOT HAVE AN FDA-LABELED LIMITATION OF USE OR CONTRAINDICATION TO THERAPY.

Required Medical Information

(1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) FOR NEUROLOGY: DOCUMENTED FAILURE WITH ONE PREFERRED AGENT, SUCH AS AUBAGIO, AVONEX, GLATIRAMER 40MG, EXTAVIA, GILENYA, GLATOPA 20MG, GLATIRAMER 20MG, PLEGRIDY, REBIF, OR TECFIDERA, OR FOR GASTROENTEROLOGY: DOCUMENTATION OF AN INADEQUATE RESPONSE TO CONVENTIONAL THERAPY, SUCH AS MERCAPTOPYRINE, AZATHIOPRINE OR METHOTREXATE, OR WITH MEDICAL NECESSITY FOR EARLIER USE OF TYSABRI.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY NEUROLOGY AND GASTROENTEROLOGY

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

VALCHLOR

Drugs

VALCHLOR

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

INITIAL CRITERIA FOR NEW START PATIENTS: (1) FOR THE TOPICAL TREATMENT OF STAGE 1A OR 1B MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN-DIRECTED THERAPY. RENEWAL CRITERIA: DOCUMENTATION OF BENEFICIAL RESPONSE

Age Restriction

Prescriber Restriction

Coverage Duration

THREE MONTHS, THEN BALANCE OF CONTRACT YEAR IF RENEWAL CRITERIA ARE MET.

Other Criteria

APPROVALS ARE LIMITED TO A QUANTITY OF TWO 60 GRAM TUBES PER MONTH.

VIEKIRA

Drugs

TECHNIVIE, VIEKIRA PAK, VIEKIRA XR

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

(1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, (2) DOCUMENTATION OF HEPATITIS C GENOTYPE AND BASELINE VIRAL LOAD, PROVIDER ATTESTATION OF READINESS TO TREAT, PATIENT ATTESTATION OF READINESS FOR TREATMENT, AND SUBMISSION OF VIROLOGIC RESPONSE UPON COMPLETION OF TREATMENT, AND (3) DOCUMENTED CLINICAL INAPPROPRIATENESS OF OR INABILITY TO TOLERATE HARVONI, EPCLUSA, OR MAVYRET.

Age Restriction

RESERVED FOR PATIENTS AGE 18 AND OLDER.

Prescriber Restriction

RESERVED FOR PRESCRIBING BY GASTROENTEROLOGY, HEPATOLOGY, INFECTIOUS DISEASE SPECIALISTS, OR TRANSPLANT SPECIALIST.

Coverage Duration

DURATION PER GENOTYPE AND DIAGNOSIS. 12-24 WEEKS PER FDA APPROVED LABELING OR CLINICAL GUIDELINES.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

VIRAZOLE

Drugs

ribavirin inhalation

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

(1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, OR (2) FOR TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS INFECTION FOLLOWING STEM CELL TRANSPLANT.

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

THIS DRUG MAY BE COVERED UNDER MEDICARE PART B OR PART D DEPENDING ON THE CIRCUMSTANCES. INFORMATION MAY NEED TO BE SUBMITTED DESCRIBING THE USE OF THE DRUG AND SETTING WHERE THE DRUG IS DISPENSED TO MAKE THE PART B OR PART D COVERAGE DETERMINATION.

VORAXAPAR

Drugs

ZONTIVITY

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

(1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) DOCUMENTATION OF MEDICAL CONTRAINDICATIONS OR INADEQUATE RESPONSE TO CONCOMITANT ASPIRIN AND CLOPIDOGREL.

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

VOSEVI

Drugs **VOSEVI**

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

(1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) DOCUMENTATION OF HEPATITIS C GENOTYPE AND BASELINE VIRAL LOAD, PROVIDER ATTESTATION OF READINESS TO TREAT, PATIENT ATTESTATION OF READINESS FOR TREATMENT, AND SUBMISSION OF VIROLOGIC RESPONSE UPON COMPLETION OF TREATMENT.

Age Restriction

RESERVED FOR PATIENTS AGE 18 AND OLDER.

Prescriber Restriction

RESERVED FOR PRESCRIBING BY GASTROENTEROLOGY, HEPATOLOGY, INFECTIOUS DISEASE SPECIALISTS, OR TRANSPLANT SPECIALIST.

Coverage Duration

12 WKS PER DIAGNOSIS, FDA LABELING OR CLINICAL GUIDELINES.

Other Criteria

DOSE IS LIMITED TO THE FDA-APPROVED REGIMEN OF ONE TABLET DAILY.

XATMEP

Drugs

XATMEP

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

FOR NEW START PATIENTS: (1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) DOCUMENTATION THAT THE PATIENT HAS DIFFICULTY SWALLOWING OR HAS COMPLIANCE CONCERNS WITH METHOTREXATE TABLETS OR INJECTION.

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

THIS DRUG MAY BE COVERED UNDER MEDICARE PART B OR PART D DEPENDING ON THE CIRCUMSTANCES. INFORMATION MAY NEED TO BE SUBMITTED DESCRIBING THE USE OF THE DRUG AND SETTING WHERE THE DRUG IS DISPENSED TO MAKE THE PART B OR PART D COVERAGE DETERMINATION.

XELJANZ

Drugs

XELJANZ, XELJANZ XR

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

MAY NOT USE XELJANZ CONCURRENTLY WITH OTHER BIOLOGIC THERAPIES.

Required Medical Information

INITIAL CRITERIA: (1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) MEDICAL CHART DOCUMENTATION OF BASELINE DISEASE ACTIVITY AND/OR FUNCTIONAL ASSESSMENT AND TREATMENT GOALS, AND (3) FOR RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS: MEDICAL CHART DOCUMENTATION OF CONTRAINDICATIONS OR INADEQUATE RESPONSE WITH ENBREL AND HUMIRA, OR FOR ULCERATIVE COLITIS: DOCUMENTATION OF MEDICAL CONTRAINDICATIONS OR INADEQUATE RESPONSE TO HUMIRA. RENEWAL CRITERIA: MEDICAL CHART DOCUMENTATION THAT TREATMENT GOALS HAVE BEEN MET FOR THERAPY.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY RHEUMATOLOGY OR GASTROENTEROLOGY.

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

XENAZINE

Drugs

tetrabenazine

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D.

RENEWAL CRITERIA: DOCUMENTATION OF POSITIVE RESPONSE TO THERAPY.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY NEUROLOGY.

Coverage Duration

THREE MONTHS, THEN BALANCE OF CONTRACT YEAR IF POSITIVE RESPONSE.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

XERMELO

Drugs

XERMELO

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

INITIAL CRITERIA: DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D. RENEWAL CRITERIA: DOCUMENTATION OF POSITIVE RESPONSE.

Age Restriction

Prescriber Restriction

Coverage Duration

SIX MONTHS, THEN BALANCE OF CONTRACT YEAR IF RENEWAL CRITERIA ARE MET.

Other Criteria

XGEVA

Drugs XGEVA

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

(1) FOR PREVENTION OF SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE METASTASES FROM SOLID TUMORS WITH INADEQUATE RESPONSE OR MEDICAL CONTRAINDICATION TO ZOLEDRONIC ACID, OR (2) FOR TREATMENT OF ADULTS AND SKELATALLY MATURE ADOLESCENTS WITH GIANT CELL TUMOR OF BONE THAT IS UNRESECTABLE OR WHERE SURGICAL RESECTION IS LIKELY TO RESULT IN SEVERE MORBIDITY, OR (3) DIAGNOSIS OF HYPERCALCEMIA OF MALIGNANCY REFRACTORY TO BISPHOSPHONATE THERAPY.

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

XIFAXAN

Drugs

XIFAXAN

Covered Uses

ALL MEDICALLY ACCEPTED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

(1) DIAGNOSIS OF HEPATIC ENCEPHALOPATHY AND DOCUMENTATION THAT SIDE EFFECTS HAVE LIMITED THE DOSE OF LACTULOSE, OR (2) DIAGNOSIS OF TRAVELER'S DIARRHEA AND DOCUMENTATION OF TRIAL AND FAILURE OF OR CONTRAINDICATIONS TO CIPROFLOXACIN, OR (3) DIAGNOSIS OF MODERATE TO SEVERE IRRITABLE BOWEL DISEASE, INCLUDING BLOATING, WITHOUT CONSTIPATION AND WITH (A) AN INADEQUATE RESPONSE TO FIRST LINE THERAPY INCLUDING AN ANTISPASMODIC AGENT SUCH AS DICYCLOMINE AND AN ANTIDIARRHEAL AGENT SUCH AS LOPERAMIDE OR DIPHENOXYLATE/ATROPINE.

Age Restriction

Prescriber Restriction

RESERVED FOR PRESCRIBING BY GASTROENTEROLOGY FOR TREATMENT OF IRRITABLE BOWEL DISEASE

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

IRRITABLE BOWEL DISEASE: DOSE IS LIMITED TO 550 MG THREE TIMES DAILY FOR 14 DAYS. RETREATMENT IS LIMITED TO PATIENTS WITH A POSITIVE RESPONSE AND LIMITED TO A MAXIMUM OF TWO, 14 DAY TREATMENTS.

XOLAIR

Drugs

XOLAIR

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

PATIENT MUST NOT HAVE AN FDA-LABELED LIMITATION OF USE OR CONTRAINDICATION TO THERAPY.

Required Medical Information

DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (1) FOR ASTHMA: DOCUMENTATION OF FAILURE WITH AT LEAST TWO OF THE FOLLOWING STANDARD THERAPIES: (A) REGULAR USE OF INHALED STEROIDS (SUCH AS FLOVENT), (B) REGULAR USE OF A LONG-ACTING BETA-AGONIST (SUCH AS SEREVENT), (C) REGULAR USE OR A TRIAL OF A LEUKOTRIENE ANTAGONIST (SUCH AS MONTELUKAST), AND (D) REGULAR OR PERIODIC USE OF ORAL STEROIDS (SUCH AS PREDNISONE), OR (2) FOR CHRONIC URTICARIA: SYMPTOMS FOR LONGER THAN 6 MONTHS, AND DOCUMENTATION OF FAILURE WITH AT LEAST TWO OF THE STANDARD THERAPIES: (A) AN H1 ANTIHISTAMINE (SUCH AS LEVOCETIRIZINE), (B) AN H2 ANTIHISTAMINE (SUCH AS FAMOTIDINE), (C) LEUKOTRIENE ANTAGONIST (SUCH AS MONTELUKAST), AND (D) MULTIPLE COURSES OF OR DEPENDENT ON AN ORAL STEROID (SUCH AS PREDNISONE).

Age Restriction

Prescriber Restriction

FOR CHRONIC URTICARIA: RESERVED FOR PRESCRIBING BY AN ALLERGIST, IMMUNOLOGIST, OR DERMATOLOGIST.

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

XTANDI

Drugs

XTANDI

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

INITIAL CRITERIA FOR NEW START PATIENTS: (1) DIAGNOSIS OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, AND (2) PRIOR TREATMENT WITH ABIRATERONE (ZYTIGA) WITH NEW DISEASE PROGRESSION OR IN CASES WHERE ABIRATERONE REGIMENS ARE CONTRAINDICATED OR NOT TOLERATED. RENEWAL CRITERIA: DOCUMENTATION OF NO DISEASE PROGRESSION AND NO NEW CHEMOTHERAPY REGIMENS. FAILURE IS DEFINED AS SYMPTOMS OF PROGRESSIVE DISEASE OR A SUSTAINED INCREASE IN PSA OF 25-30% OVER AT LEAST TWO MONTHS.

Age Restriction

Prescriber Restriction

Coverage Duration

SIX MONTHS, THEN BALANCE OF CONTRACT YEAR IF RENEWAL CRITERIA ARE MET.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

ZALTRAP

Drugs

ZALTRAP

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

INITIAL CRITERIA FOR NEW START PATIENTS: DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D. RENEWAL CRITERIA: DOCUMENTATION THAT DISEASE PROGRESSION HAS NOT OCCURRED.

Age Restriction

Prescriber Restriction

Coverage Duration

THREE MONTHS, THEN BALANCE OF CONTRACT YEAR IF RENEWAL CRITERIA ARE MET.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

ZYFLO

Drugs

zileuton

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

(1) DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D, AND (2) DOCUMENTATION OF FAILURE WITH MONTELUKAST.

Age Restriction

Prescriber Restriction

Coverage Duration

CONTRACT YEAR, BALANCE OF CONTRACT YEAR, OR FDA-APPROVED DURATION, WHICHEVER IS APPLICABLE FOR USE.

Other Criteria

ZYTIGA

Drugs

abiraterone, ZYTIGA

Covered Uses

ALL FDA-APPROVED INDICATIONS, NOT OTHERWISE EXCLUDED FROM PART D.

Exclusion Criteria

Required Medical Information

INITIAL CRITERIA FOR NEW START PATIENTS: DIAGNOSIS OF AN FDA-APPROVED INDICATION, NOT OTHERWISE EXCLUDED FROM PART D. RENEWAL CRITERIA: DOCUMENTATION THAT (1) DISEASE PROGRESSION HAS NOT OCCURRED, AND (2) NO OTHER CHEMOTHERAPY REGIMENS HAVE BEEN INITIATED. FAILURE IS DEFINED AS SYMPTOMS OF PROGRESSIVE DISEASE OR A SUSTAINED INCREASE IN PSA OF 25-30% OVER AT LEAST TWO MONTHS.

Age Restriction

Prescriber Restriction

Coverage Duration

SIX MONTHS, THEN BALANCE OF CONTRACT YEAR IF RENEWAL CRITERIA ARE MET.

Other Criteria

LIMITED TO A DOSE WITHIN THE FDA LABELED DOSING GUIDELINES.

Index

ABELCET	39	APTIOM	5	CABOMETYX	78
ABILIFY MAINTENA	37	ARALAST NP		CALQUENCE	78
<i>abiraterone</i>	133	INTRAVENOUS RECON		CAMPTOSAR	
ABRAXANE	7	SOLN 1,000 MG	37	INTRAVENOUS SOLUTION	
<i>acetylcysteine</i>	85	ARANESP (IN		300 MG/15 ML	7
ACTEMRA	1	POLYSORBATE)	34	CAPASTAT	37
ACTEMRA ACTPEN	1	ARCALYST	64	CARBAGLU	64
ACTIMMUNE	2	<i>aripiprazole oral</i>		<i>carboplatin intravenous solution</i> ..	7
<i>acyclovir sodium intravenous</i>		<i>tablet, disintegrating</i>	76	CARIMUNE NF	
<i>recon soln 500 mg</i>	85	ARISTADA	37	NANOFILTERED	
<i>acyclovir sodium intravenous</i>		ARISTADA INITIO	37	INTRAVENOUS RECON	
<i>solution</i>	85	<i>armodafinil oral tablet 150 mg,</i>		SOLN 12 GRAM, 6 GRAM	39
ADAGEN	32	<i>200 mg, 250 mg, 50 mg</i>	62	<i>carmustine</i>	7
ADEMPAS	94	ARRANON	7	<i>casprofungin</i>	37
AIMOVIG AUTOINJECTOR ..	3	<i>arsenic trioxide</i>	7	CAYSTON	37
AIMOVIG AUTOINJECTOR		ARZERRA	7	CERDELGA	32
(2 PACK)	3	ATGAM	37	<i>chloramphenicol sod succinate</i> ..	37
AJOVY	3	AUSTEDO	11	CHOLBAM	32
<i>albuterol sulfate inhalation</i>		AVASTIN	7	CHORIONIC	
<i>solution for nebulization 0.63</i>		<i>azacitidine</i>	7	GONADOTROPIN, HUMAN ..	37
<i>mg/3 ml, 1.25 mg/3 ml, 2.5 mg</i>		AZASAN	85	CIMZIA	14
<i>/3 ml (0.083 %), 5 mg/ml</i>	85	<i>azathioprine</i>	85	CIMZIA POWDER FOR	
ALDURAZYME	32	<i>azathioprine sodium</i>	85	RECONST	14
ALECENSA	78	BANZEL ORAL		CINRYZE	37
ALIMTA	7	SUSPENSION	5	<i>cisplatin</i>	7
ALIQOPA	7	BANZEL ORAL TABLET		<i>cladribine</i>	8
<i>alosetron</i>	58	200 MG, 400 MG	5	<i>clofarabine</i>	7
ALUNBRIG	78	BAVENCIO	7	<i>clomipramine</i>	15
AMBISOME	39	BCG VACCINE, LIVE (PF) ... 85		<i>clonidine hcl oral tablet</i>	
<i>amifostine crystalline</i>	7	BELEODAQ	7	<i>extended release 12 hr</i>	16
<i>amikacin injection solution</i>		BENDEKA	7	<i>clozapine oral</i>	
<i>1,000 mg/4 ml, 500 mg/2 ml</i>	37	BENLYSTA	37	<i>tablet, disintegrating</i>	76
AMINOSYN 8.5 %-		BERINERT INTRAVENOUS		COMETRIQ	78
ELECTROLYTES	85	KIT	37	COPAXONE	
AMINOSYN II 10 %	85	BESPONSA	7	SUBCUTANEOUS SYRINGE	
AMINOSYN II 15 %	85	BETASERON		20 MG/ML	17
AMINOSYN II 7 %	85	SUBCUTANEOUS KIT	12	COPAXONE	
AMINOSYN II 8.5 %	85	BETHKIS	71	SUBCUTANEOUS SYRINGE	
AMINOSYN II 8.5 %-		BICNU	7	40 MG/ML	18
ELECTROLYTES	85	BIVIGAM	39	COPIKTRA	78
AMINOSYN M 3.5 %	85	<i>bleomycin</i>	8	CORLANOR	37
AMINOSYN-HBC 7%	85	BLINCYTO INTRAVENOUS		COSENTYX (2 SYRINGES) ... 19	
AMINOSYN-PF 10 %	85	KIT	7	COSENTYX PEN (2 PENS) ... 19	
AMINOSYN-PF 7 %		BORTEZOMIB	7	COTELLIC	78
(SULFITE-FREE)	85	BOSULIF	78	CRESEMBA ORAL	50
<i>amitriptyline</i>	114	BRAFTOVI	78	<i>cromolyn inhalation</i>	85
<i>amphotericin b</i>	39	BRIVIACT	13	CUVITRU	39
ANADROL-50	37	<i>budesonide inhalation</i>	85	<i>cyclobenzaprine oral tablet 10</i>	
APOKYN	37	<i>buprenorphine</i>	46	<i>mg, 5 mg</i>	62
<i>aprepitant</i>	85	<i>busulfan</i>	7	<i>cyclophosphamide oral capsule</i> ..	85

<i>cycloserine</i>	37	EMEND ORAL	GALAFOLD	43
<i>cyclosporine intravenous</i>	85	SUSPENSION FOR	GAMASTAN S/D	39
<i>cyclosporine modified</i>	85	RECONSTITUTION	GAMMAGARD LIQUID	39
<i>cyclosporine oral capsule</i>	85	EMGALITY PEN	GAMMAGARD S-D (IGA < 1	
CYRAMZA	7	EMGALITY SYRINGE	MCG/ML)	39
CYSTARAN	20	EMPLICITI	GAMMAKED	39
<i>cytarabine</i>	8	EMSAM	GAMMAPLEX	39
<i>cytarabine (pf) injection solution</i>		ENBREL	GAMMAPLEX (WITH	
<i>100 mg/5 ml (20 mg/ml), 2</i>		ENBREL SURECLICK	SORBITOL)	39
<i>gram/20 ml (100 mg/ml)</i>	8	ENGERIX-B (PF)	GAMUNEX-C	39
<i>dacarbazine</i>	7	ENGERIX-B PEDIATRIC	<i>ganciclovir sodium</i>	85
<i>dactinomycin</i>	7	(PF) INTRAMUSCULAR	GATTEX 30-VIAL	44
DAKLINZA	21	SYRINGE	GAZYVA	7
<i>dalfampridine</i>	22	EPCLUSA	<i>gemcitabine</i>	7
DALIRESP	23	EPIDIOLEX	<i>gengraf</i>	85
<i>daptomycin</i>	37	<i>epirubicin</i>	GILOTRIF	78
DARZALEX	7	<i>epoprostenol (glycine)</i>	GLASSIA	37
<i>daunorubicin</i>	7	ERAXIS(WATER DILUENT)	<i>granisetron hcl oral</i>	85
DAURISMO	78	ERBITUX	GRASTEK	107
<i>decitabine</i>	7	ERIVEDGE	HAEGARDA	37
<i>deltasone oral tablet 20 mg</i>	85	ERLEADA	HALAVEN	7
DEMSEER	37	ERWINAZE	HARVONI	45
DEPEN TITRATABS	88	ESBRIET	<i>heparin (porcine) in 5 % dex</i>	
DEPO-PROVERA		EUCRISA	<i>intravenous parenteral solution</i>	
INTRAMUSCULAR		EXJADE	<i>20,000 unit/500 ml (40 unit/ml)</i> ..	85
SUSPENSION 400 MG/ML	63	FABRAZYME	HERCEPTIN	7
<i>desvenlafaxine succinate</i>	24	<i>famotidine (pf)</i>	HETLIOZ	37
<i>dexamethasone oral elixir</i>	85	<i>famotidine intravenous solution</i> ..	HIZENTRA	39
<i>dexamethasone oral tablet</i>	85	FANAPT	HUMIRA	48
<i>dexrazoxane hcl</i>	37	FARYDAK	HUMIRA PEDIATRIC	
DIFICID	25	FASLODEX	CROHNS START	48
<i>digitek oral tablet 250 mcg</i>	26	<i>fentanyl citrate buccal lozenge</i>	HUMIRA PEN	48
<i>digox oral tablet 250 mcg</i>	26	<i>on a handle 200 mcg, 400 mcg</i> ...68	HUMIRA PEN CROHNS-UC-	
<i>digoxin oral tablet 250 mcg</i>	26	<i>fentanyl transdermal patch 72</i>	HS START	48
<i>dihydroergotamine</i>	27	<i>hour 100 mcg/hr, 12 mcg/hr, 25</i>	HUMIRA PEN PSOR-	
<i>docetaxel intravenous solution</i>		<i>mcg/hr, 50 mcg/hr, 75 mcg/hr</i>	UVEITS-ADOL HS	48
<i>160 mg/8 ml (20 mg/ml), 20</i>		FERRIPROX	HUMIRA(CF)	48
<i>mg/2 ml (10 mg/ml), 20 mg/ml,</i>		FETZIMA	HUMIRA(CF) PEDI	
<i>20 mg/ml (1 ml), 80 mg/4 ml (20</i>		FIRAZYR	CROHNS STARTER	48
<i>mg/ml), 80 mg/8 ml (10 mg/ml)</i>	7	FLEBOGAMMA DIF	HUMIRA(CF) PEN	48
<i>doxepin oral</i>	114	<i>fludarabine</i>	HUMIRA(CF) PEN	
<i>doxorubicin intravenous</i>		<i>fluorouracil intravenous</i>	CROHNS-UC-HS	48
<i>solution</i>	8	<i>solution 1 gram/20 ml, 5</i>	HUMIRA(CF) PEN PSOR-	
<i>doxorubicin, peg-liposomal</i>	8	<i>gram/100 ml, 500 mg/10 ml</i>	UV-ADOL HS	48
<i>d-penaminate</i>	88	FOLOTYN	HYQVIA	39
<i>dronabinol oral capsule 10 mg,</i>		<i>fomepizole</i>	IBRANCE	78
<i>2.5 mg, 5 mg</i>	85	<i>fondaparinux</i>	ICLUSIG	78
DULERA	28	FORTEO	<i>idarubicin</i>	7
DUPIXENT	29	<i>foscarnet</i>	IDHIFA	78
ELAPRASE	32	FYCOMPA ORAL	<i>ifosfamide</i>	7
ELELYSO	32	SUSPENSION		
ELITEK	32	FYCOMPA ORAL TABLET		

ILARIS (PF)			
SUBCUTANEOUS SOLUTION	32	LEVOLEUCOVORIN CALCIUM INTRAVENOUS RECON SOLN 175 MG	37
IMBRUVICA	78	<i>levoleucovorin calcium intravenous recon soln 50 mg</i>	37
IMFINZI	7	<i>levoleucovorin calcium intravenous solution</i>	37
<i>imipramine hcl</i>	114	LIBTAYO	7
IMLYGIC	8	<i>lidocaine topical adhesive patch, medicated</i>	57
IMOVAX RABIES VACCINE (PF)	85	<i>linezolid</i>	50
INCRELEX	61	<i>linezolid in dextrose 5%</i>	50
INGREZZA	51	LONSURF	78
INLYTA	78	LORBRENA	78
INTRALIPID INTRAVENOUS EMULSION 20 %, 30 %	85	LUMIZYME	32
INVEGA SUSTENNA	37	LUMOXITI	7
INVEGA TRINZA	37	LUPRON DEPOT	7
<i>ipratropium bromide inhalation</i>	85	LUPRON DEPOT (3 MONTH)	7
<i>ipratropium-albuterol</i>	85	LUPRON DEPOT (4 MONTH)	7
IRESSA	78	LUPRON DEPOT (6 MONTH)	7
<i>irinotecan</i>	7	LUPRON DEPOT-PED (3 MONTH)	7
<i>itraconazole</i>	52	INTRAMUSCULAR SYRINGE KIT 30 MG	37
IXEMPRA	7	LUPRON DEPOT-PED INTRAMUSCULAR KIT 11.25 MG, 15 MG	37
JADENU	111	LYNPARZA	78
JADENU SPRINKLE	111	MARQIBO	59
JAKAFI	78	MATULANE	91
JEVTANA	7	MAVYRET	60
JUXTAPID	47	MEKINIST	78
KADCYLA	7	MEKTOVI	78
KALBITOR	37	<i>melphalan hcl</i>	7
KALYDECO	53	<i>mesna</i>	37
KEPIVANCE	37	<i>methadone oral concentrate</i>	46
KEVZARA	54	<i>methadone oral solution</i>	46
KEYTRUDA INTRAVENOUS SOLUTION ..	7	<i>methadone oral tablet</i>	46
KHAPZORY	37	<i>methotrexate sodium</i>	85
KINERET	55	<i>methotrexate sodium (pf) injection solution</i>	85
KISQALI	78	<i>methoxsalen</i>	65
KISQALI FEMARA CO-PACK	78	<i>methylprednisolone oral tablet</i>	85
KORLYM	37	MIACALCIN INJECTION	66
KRYSTEXXA	37	MILLIPRED ORAL TABLET	85
KUVAN	64	<i>mitomycin intravenous</i>	7
KYNAMRO	47	<i>mitoxantrone</i>	7
KYPROLIS	7	<i>modafinil</i>	62
LARTRUVO	7	<i>morphine oral tablet extended release 15 mg, 30 mg, 60 mg</i>	46
LATUDA	56	MOVANTIK	37
LAZANDA	68	MOZOBIL	37
<i>ledipasvir-sofosbuvir</i>	45	MULTAQ	67
LENVIMA	78	MUSTARGEN	7
LETAIRIS	94	<i>mutamycin</i>	7
		<i>mycophenolate mofetil</i>	85
		<i>mycophenolate mofetil hcl</i>	85
		MYLOTARG	7
		MYTESI	42
		NAGLAZYME	32
		NATPARA	69
		NEBUPENT	85
		NERLYNX	78
		NEUPRO	9
		NINLARO	78
		NORDITROPIN FLEXPRO	105
		NORTHERA ORAL CAPSULE 100 MG, 200 MG, 300 MG	72
		NOXAFIL ORAL	50
		NUEDEXTA	73
		NULOJIX	85
		NUPLAZID	37
		OCTAGAM	39
		ODOMZO	78
		OFEV	49
		<i>olanzapine oral tablet, disintegrating</i>	76
		OLUMIANT	74
		OLYSIO	75
		ONCASPAR	7
		<i>ondansetron</i>	85
		<i>ondansetron hcl oral</i>	85
		ONIVYDE	7
		OPDIVO	7
		OPSUMIT	94
		ORENCIA	79
		ORENCIA (WITH MALTOSE)	79
		ORENCIA CLICKJECT	79
		ORENITRAM	80
		ORFADIN	32
		ORLISSA ORAL TABLET 150 MG, 200 MG	81
		ORKAMBI	53
		OTEZLA	82
		OTEZLA STARTER	82
		<i>oxaliplatin</i>	7
		<i>oxandrolone oral tablet 10 mg, 2.5 mg</i>	37

<i>paclitaxel</i>	7	REMODULIN	93	SYNAGIS	37
<i>paliperidone</i>	10	REPATHA PUSHTRONEX	97	SYNAREL	37
<i>pantoprazole intravenous</i>	83	REPATHA SURECLICK	97	SYNRIBO	108
<i>paricalcitol oral</i>	84	REPATHA SYRINGE	97	<i>tacrolimus oral</i>	85
PEGASYS	86	RETACRIT	34	<i>tadalafil (antihypertensive)</i>	109
PEGASYS PROCLICK	86	REXULTI	10	TAFINLAR	78
PEGINTRON		<i>ribavirin inhalation</i>	120	TAGRISSE	78
SUBCUTANEOUS KIT 50		<i>rifampin intravenous</i>	37	TAKHZYRO	37
MCG/0.5 ML	87	<i>risperidone oral</i>		TALTZ AUTOINJECTOR ...	110
PERJETA	7	<i>tablet, disintegrating</i>	76	TALTZ SYRINGE	110
PERSERIS	37	RITUXAN	98	TALZENNA	78
<i>phenoxybenzamine</i>	89	RITUXAN HYCELA	7	TARGRETIN TOPICAL	37
POMALYST	78	<i>romidepsin</i>	7	TECENTRIQ	7
PORTRAZZA	7	RUBRACA	78	TECHNIVIE	119
POTELIGEO	7	RUCONEST	37	TEMODAR INTRAVENOUS ...	7
PRADAXA	90	RYDAPT	78	<i>temsirolimus</i>	7
<i>prednisolone oral solution 15</i>		SABRIL ORAL TABLET	99	<i>testosterone cypionate</i>	4
<i>mg/5 ml</i>	85	SAPHRIS	10	<i>testosterone enanthate</i>	4
<i>prednisolone sodium phosphate</i>		SAPHRIS (BLACK		<i>testosterone transdermal gel in</i>	
<i>oral solution 10 mg/5 ml, 20</i>		CHERRY)	10	<i>metered-dose pump</i>	4
<i>mg/5 ml (4 mg/ml), 25 mg/5 ml</i>		SEROSTIM		<i>testosterone transdermal gel in</i>	
<i>(5 mg/ml), 5 mg base/5 ml (6.7</i>		SUBCUTANEOUS RECON		<i>packet</i>	4
<i>mg/5 ml)</i>	85	SOLN 4 MG, 5 MG, 6 MG ...	100	<i>tetrabenazine</i>	125
PREDNISONE INTENSOL ...	85	SIGNIFOR	101	THIOLA	112
<i>prednisone oral solution</i>	85	SIGNIFOR LAR	70	<i>thiotepa</i>	7
<i>prednisone oral tablet</i>	85	<i>sildenafil (antihypertensive)</i>		TIBSOVO	78
PRIVIGEN	39	93, 102	TICE BCG	85
PROCRIT	34	SILIQ	103	TOBI PODHALER	
PROGRAF INTRAVENOUS ..	85	SIMPONI	104	INHALATION CAPSULE,	
PROLASTIN-C		SIMULECT	85	W/INHALATION DEVICE ...	37
INTRAVENOUS RECON		<i>sirolimus</i>	85	<i>tobramycin in 0.225 % nacl</i>	39
SOLN	37	SIRTURO	37	<i>tobramycin sulfate injection</i>	
PROLEUKIN	7	SIVEXTRO	50	<i>solution</i>	37
PROMACTA	92	<i>sodium phenylbutyrate oral</i>		TORISEL	7
PULMOZYME	39	<i>tablet</i>	37	TRACLEER	94
<i>quinine sulfate</i>	37	<i>sofosbuvir-velpatasvir</i>	33	<i>tranexamic acid intravenous</i>	37
RABAVERT (PF)	85	SOLIRIS	37	TREANDA INTRAVENOUS	
RAGWITEK	107	SOMATULINE DEPOT		RECON SOLN	7
RANEXA	37	SUBCUTANEOUS SYRINGE		TRELSTAR	7
RAPAMUNE ORAL		120 MG/0.5 ML, 60 MG/0.2		TREMFYA	113
SOLUTION	85	ML, 90 MG/0.3 ML	37	<i>trientine</i>	115
RASUVO (PF)		SOMAVERT	37	<i>trimethobenzamide oral</i>	85
SUBCUTANEOUS AUTO-		SPORANOX ORAL		<i>trimipramine</i>	114
INJECTOR 10 MG/0.2 ML,		SOLUTION	52	TRINTELLIX	6
12.5 MG/0.25 ML, 15 MG/0.3		SPRITAM	76	TRISENOX INTRAVENOUS	
ML, 17.5 MG/0.35 ML, 20		STELARA	106	SOLUTION 2 MG/ML	7
MG/0.4 ML, 22.5 MG/0.45		STIVARGA	78	TYMLOS	116
ML, 25 MG/0.5 ML, 30		STRENSIQ	38	TYSABRI	117
MG/0.6 ML, 7.5 MG/0.15 ML .	95	SUCRAID	64	TYVASO	93
RAVICTI	64	SYLVANT	7	UNITUXIN	7
RECOMBIVAX HB (PF)	85	SYMDEKO	53	UPTRAVI	94
REMICADE	96	SYMPROIC	37	UVADEX	7

VALCHLOR	118	ZORBTIVE	37
VECTIBIX	7	ZORTRESS	39
VELCADE	7	ZYDELIG	78
VELETRI	93	ZYKADIA	78
VENCLEXTA	78	ZYPREXA RELPREVV	37
VENCLEXTA STARTING PACK	78	ZYTIGA	133
VENTAVIS	93		
VERSACLOZ	77		
VERZENIO	78		
VIEKIRA PAK	119		
VIEKIRA XR	119		
<i>vigabatrin</i>	99		
<i>vigadrone</i>	99		
VIIBRYD ORAL TABLET	6		
VIIBRYD ORAL TABLETS,DOSE PACK 10			
MG (7)- 20 MG (23)	6		
<i>vinblastine intravenous solution</i> ...	8		
<i>vincasar pfs</i>	7		
<i>vincristine</i>	7		
<i>vinorelbine</i>	7		
VISTOGARD	37		
VITRAKVI	78		
VIZIMPRO	78		
<i>voriconazole</i>	50		
VOSEVI	122		
VPRIV	32		
VRAYLAR	10		
VYXEOS	7		
XALKORI	78		
XATMEP	123		
XELJANZ	124		
XELJANZ XR	124		
XERMELO	126		
XGEVA	127		
XIFAXAN	128		
XOLAIR	129		
XOSPATA	78		
XTANDI	130		
XYREM	37		
YERVOY	7		
YONDELIS	8		
YONSA	78		
ZALTRAP	131		
ZANOSAR	7		
ZEJULA	78		
ZELBORAF	78		
ZEMAIRA	37		
<i>zileuton</i>	132		
ZOLINZA	78		
ZONTIVITY	121		